(11) EP 0 688 869 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
19.03.2003 Bulletin 2003/12

(51) Int CI.7: **C12N 15/12**, C07K 14/51, C12N 5/10, C12N 1/21, A61K 38/18

(21) Application number: 95111771.2

(22) Date of filing: 30.06.1987

(54) Novel osteoinductive compositions

Osteoinduktive Zusammensetzungen Compositions ostéoinductrices

(84) Designated Contracting States:

AT BE CH DE FR GB IT LI LU NL SE

(30) Priority: 01.07.1986 US 880776 17.12.1986 US 943332 20.03.1987 US 28285 26.03.1987 US 31346

(43) Date of publication of application: 27.12.1995 Bulletin 1995/52

(60) Divisional application: 02014841.7 / 1 254 956

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: 87905023.5 / 0 313 578 (73) Proprietor: Genetics Institute, LLC Cambridge, MA 02140 (US)

(72) Inventors:

Wang, Elizabeth A.
 Carlisle, MA 01741 (US)

 Wozney, John M. Hudson, MA 01749 (US)

Rosen, Vicki A.
 Boston, MA 02116 (US)

(74) Representative: VOSSIUS & PARTNER
Postfach 86 07 67
81634 München (DE)

(56) References cited: US-A- 4 455 256

O 688 869 B

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The present invention relates to novel proteins and processes for obtaining them. These proteins are capable of inducing cartilage and bone formation.

Background

5

10

15

20

35

[0002] Bone is a highly specialized tissue characterized by an extensive matrix structure formed of fibrous bundles of the protein collagen, and proteoglycans, noncollagenous proteins, lipids and acidic proteins. The processes of bone formation and renewal/repair of bone tissue, which occur continuously throughout life, are performed by specialized cells. Normal embryonic long bone development is preceded by formation of a cartilage model. Bone growth is presumably mediated by "osteoblasts" (bone-forming cells), while remodeling of bone is apparently accomplished by the joint activities of bone-resorbing cells, called "osteoclasts" and osteoblasts. A variety of osteogenic, cartilage-inducing and bone inducing factors have been described. See, e.g. European patent applications 148,155 and 169,016 for discussions thereof.

Brief Description of the Invention

[0003] The present invention provides a novel protein in purified form BMP-3, wherein BMP is bone morphogenic protein. This protein is characterized by peptide sequences the same as or substantially homologous to amino acid sequences illustrated in Tables IV A+B below. It is capable of inducing bone formation at a predetermined site. This bone inductive factor is further characterized by biochemical and biological characteristics including activity at a concentration of 10 to 1000ng/gram of bone in an in vivo rat bone formation assay described below. Proteins of this invention may be encoded by the DNA sequences depicted in the Tables or by sequences capable of hybridizing thereto unden strigent conditions and coding for polypeptides with bone growth factor biological properties or other variously modified sequences demonstrating such properties.

[0004] The pone inductive factor of the invention, BMP-3, is represented by the bovine homolog bBMP-3. bBMP-3 is characterized by the DNA sequence and amino acid sequence of Table IV A and B which represents the bovine genomic sequence. It is characterized by at least a portion of a peptide sequence the same or substantially the same as amino acid #1 through amino acid #175 of Table IV A and B. BMP-3 is further characterized by the ability to induce bone formation. The bovine factor may be employed as a tool for obtaining the analogous human BMP-3 protein or other mammalian bone inductive proteins. The proper characterization of this bovine bone inductive factor provides the essential "starting point" for the method employing this sequence. The method, employing techniques known to those skilled in the art of genetic engineering, involves using the bovine DNA sequence as a probe to screen a human genomic or cDNA library; and identifying the DNA sequences which hybridize to the probes. A clone with a hybridizable sequence is plaque purified and the DNA isolated therefrom, subcloned and subjected to DNA sequence analysis. Thus another aspect of this invention is a human protein hBMP-3, produced by this method.

[0005] Another aspect of the invention provides pharmaceutical compositions containing a therapeutically effective amount of the bone growth factor polypeptide according to the invention in a pharmaceutically acceptable vehicle. These compositions may further include other therapeutically useful agents. They may also include an appropriate matrix for delivering the proteins to the site of the bone defect and for providing a structure for bone growth. These compositions may be employed in methods for treating a number of bone defects and periodontal disease. These methods, according to the invention, entail administering to a patient needing such bone formation an effective amount of the novel protein BMP-3 as described herein.

[0006] Still a further aspect of the invention are DNA sequences coding on expression for a human or bovine polypeptide having the ability to induce bone formation. Such sequences include the sequence or nucleotides in a 5' to 3' direction illustrated in Tables IV A+B. Alternatively, a DNA sequence which hybridizes under stringent conditions with the DNA sequences of Tables IV A+B and which codes on expression for a protein having at least one bone growth factor biological property are included in the present invention. Finally, allelic or other variations of the sequences of Tables IV A+B, whether such nucleotide changes result in changes in the peptide sequence or not, are also included in the present invention.

[0007] Still a further aspect of the invention is a vector containing a DNA sequence as described above in operative association with an expression control sequence. Such vector may be employed in a novel process for producing a bone growth factor polypeptide in which a cell line transformed with a DNA sequence encoding expression of a bone growth factor polypeptide in operative association with an expression control sequence therefor, is cultured. This claimed process may employ a number of known cells as host cells for expression of the polypeptide. Presently preferred cell lines are mammalian cell lines and bacterial cells.

[0008] Other aspects and advantages of the present invention will be apparent upon consideration of the following

detailed description and preferred embodiments thereof.

Detailed Description of the Invention

[0009] The protein of the present invention is characterized by amino acid sequences or portions thereof the same as or substantially homologous to the sequences shown in Tables IV A+B below. This protein is also characterized by the ability to induce bone formation.

[0010] The bone growth factors provided herein also include factors encoded by the sequences similar to those of Tables IV A+B, but into which modifications are naturally provided (e.g. allelic variations in the nucleotide sequence which may result in amino acid changes in the polypeptide) or deliberately engineered. For example, synthetic polypeptides may wholly or partially duplicate continuous sequences of the amino acid residues of Tables IV A+B. These sequences, by virtue of sharing primary, secondary, or tertiary structural and conformational characteristics with the bone growth factor polypeptide of Tables IV A+B may possess bone growth factor biological properties in common therewith. Thus, they may be employed as biologically active substitutes for naturally-occurring bone growth factor polypeptides in therapeutic processes.

[0011] Other specific mutations of the sequences of the bone growth factor described herein involve modifications of one or both of the glycosylation sites. The absence of glycosylation or only partial glycosylation results from amino acid substitution or deletion at one or both of the asparagine-linked glycosylation recognition sites present in the sequences of the bone growth factor shown in Tables IV A+B. The asparagine-linked glycosylation recognition sites comprise tripeptide sequences which are specifically recognized by appropriate cellular glycosylation enzymes. These tripeptide sequences are either asparagine-X-threonine or asparagine-X-serine, where X is usually any amino acid. A variety of amino acid substitutions or deletions at one or both of the first or third amino acid positions of a glycosylation recognition site (and/or amino acid deletion at the second position) results in non-glycosylation at the modified tripeptide sequence.

[0012] The present invention also encompasses the novel DNA sequences, free of association with DNA sequences encoding other proteinaceous materials, and coding on expression for bone growth factors. These DNA sequences include those depicted in Tables IV A+B in a 5' to 3' direction and those sequences which hybridize under stringent hybridization conditions [see, T. Maniatis et al, Molecular Cloning (A Laboratory Manual), Cold Spring Harbor Laboratory (1982), pages 387 to 389] to the DNA sequences of Tables IV A+B.

[0013] Similarly, DNA sequences which code for bone growth factor polypeptides coded for by the sequences of Tables IV A+B, but which differ in codon sequence due to the degeneracies of the genetic code or allelic variations (naturally-occurring base changes in the species population which may or may not result in an amino acid change) also encode the novel growth factors described herein. Variations in the DNA sequences of Tables IV A+B which are caused by point mutations or by induced modifications to enhance the activity, half-life or production of the polypeptides encoded thereby are also encompassed in the invention.

[0014] Another aspect of the present invention provides a novel method for producing the novel osteoinductive factors. The method of the present invention involves culturing a suitable cell or cell line, which has been transformed with a DNA sequence coding on expression for a novel bone growth factor polypeptide of the invention, under the control of known regulatory sequences. Suitable cells or cell lines may be mammalian cells, such as Chinese hamster ovary cells (CHO). The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, Nature, 293:620-625 (1981), or alternatively, Kaufman et al, Mol. Cell. Biol., 5(7):1750-1759 (1985) or Howley et al, U.S. Patent 4,419,446. Another suitable mammalian cell line, which is described in the accompanying examples, is the monkey COS-1 cell line. A similarly useful mammalian cell line is the CV-1 cell line.

[0015] Bacterial cells are suitable hosts. For example, the various strains of <u>E. coli</u> (e.g., HB101, MC1061) are well-known as host cells in the field of biotechnology. Various strains of B. <u>subtilis</u>, <u>Pseudomonas</u>, other bacilli and the like may also be employed in this method.

[0016] Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention. Additionally, where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g. Miller et al, <u>Genetic Engineering</u>, <u>8</u>:277-298 (Plenum Press 1986) and references, cited therein.

[0017] Another aspect of the present invention provides vectors for use in the method of expression of these novel osteoinductive polypeptides. Preferably the vectors contain the full novel DNA sequences described above which code for the novel factors of the invention. Additionally the vectors also contain appropriate expression control sequences permitting expression of the bone inductive protein sequences. Alternatively, vectors incorporating modified sequences as described above are also embodiments of the present invention and useful in the production of the bone inductive proteins. The vectors may be employed in the method of transforming cell lines and contain selected regulatory sequences in operative association with the DNA coding sequences of the invention which are capable of directing the

replication and expression thereof in selected host cells. Useful regulatory sequences for such vectors are known to one of skill in the art and may be selected depending upon the selected host cells. Such selection is routine and does not form part of the present invention.

[0018] A protein of the present invention, which induces bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures. An osteogenic preparation employing is protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery. An osteogenic factor of the invention may be valuable in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. Of course, the proteins of the invention may have other therapeutic uses.

[0019] A further aspect of the invention is a therapeutic method and composition for repairing fractures and other conditions related to bone defects or periodontal diseases. Such a composition comprises a therapeutically effective amount of the bone inductive factor protein of the invention. The bone inductive factor according to the present invention may be present in a therapeutic composition in admixture with a pharmaceutically acceptable vehicle or matrix. Further therapeutic methods and compositions of the invention comprise a therapeutic amount of a bone inductive factor of the invention with a therapeutic amount of at least one of the other bone inductive factors of the invention. Additionally, the protein according to the present invention may be co-administered with one or more different osteoinductive factors with which it may interact. Further, the bone inductive protein may be combined with other agents beneficial to the treatment of the bone defect in question. Such agents include, but are not limited to various growth factors. The preparation of such physiologically acceptable protein compositions, having due regard to pH, isotonicity, stability and the like, is within the skill of the art.

[0020] The therapeutic method includes locally administering the composition as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone damage. Preferably, the bone growth inductive factor composition would include a matrix capable of delivering the bone inductive factor to the site of bone damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of other materials presently in use for other implanted medical applications.

[0021] The choice of material is based on, for example, biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. Similarly, the application of the osteoinductive factors will define the appropriate formulation. Potential matrices for the osteoinductive factors may be biodegradable and chemically defined, such as, but not limited to calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyanhydrides; biodegradable and biologically well defined, such as bone or dermal collagen, other pure proteins or extracellular matrix components; nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics; or combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics might also be altered in composition, such as in calcium-aluminate-phosphate and processing to alter for example, pore size, particle size, particle shape, and biodegradability.

[0022] The dosage regimen will be determined by the attending physician considering various factors which modify the action of such a growth factor, e.g. amount of bone weight desired to be formed, the site of bone damage, the condition of the damaged bone, the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution. The addition of other known growth factors, such as IGF 1 (insulin like growth factor 1), to the final composition, may also effect the dosage. Generally, the dosage regimen should be in the range of approximately 10 to 10⁶ nanograms of protein per gram of bone weight desired. Progress can be monitored by periodic assessment of bone growth and/or repair, e.g. x-rays. Such therapeutic compositions are also presently valuable for veterinary applications due to the lack of species specificity in bone inductive factors. Particularly domestic animals and thoroughbred horses in addition to humans are desired patients for such treatment with the bone inductive factors of the present invention.

[0023] The following examples illustrate practice of the present invention in recovering and characterizing the bovine proteins and employing them to recover the human proteins, obtaining the human proteins and in expressing the proteins via recombinant techniques.

EXAMPLE I

25

30

40

55

Isolation of Bovine Bone Inductive Factor

[0024] Ground bovine bone powder (20-120 mesh, Helitrex) is prepared according to the procedures of M. R. Urist

et al., <u>Proc. Natl Acad. Sci USA</u>, 70:3511 (1973) with elimination of some extraction steps as identified below. Ten kgs of the ground powder is demineralized in successive changes of 0.6N HCl at 4°C over a 48 hour period with vigorous stirring. The resulting suspension is extracted for 16 hours at 4°C with 50 liters of 2M CaCl₂ and 10mM ethylenediamine-tetraacetic acid [EDTA], and followed by extraction for 4 hours in 50 liters of 0.5M EDTA. The residue is washed three times with distilled water before its resuspension in 20 liters of 4M guanidine hydrochloride [GuCl], 20mM Tris (pH 7.4), 1mM N-ethylmaleimide, 1mM iodoacetamide, 1mM phenylmethylsulfonyl fluorine as described in <u>Clin. Orthop. Rel. Res.</u>, 171: 213 (1982). After 16 to 20 hours the supernatant is removed and replaced with another 10 liters of GuCl buffer. The residue is extracted for another 24 hours.

[0025] The crude GuCl extracts are combined, concentrated approximately 20 times on a Pellicon apparatus with a 10,000 molecular weight cut-off membrane, and then dialyzed in 50mM Tris, 0.1M NaCl, 6M urea (pH7.2), the starting buffer for the first column. After extensive dialysis the protein is loaded on a 4 liter DEAF cellulose column and the unbound fractions are collected.

[0026] The unbound fractions are concentrated and dialyzed against 50mM NaAc, 50mM NaCl (pH 4.6) in 6M urea. The unbound fractions are applied to a carboxymethyl cellulose column. Protein not bound to the column is removed by extensive washing with starting buffer, and the bone inductive factor containing material desorbed from the column by 50mM NaAc, 0.25mM NaCl, 6M urea (pH 4.6). The protein from this step elution is concentrated 20- to 40- fold, then diluted 5 times with 80mM KPO₄, 6M urea (pH6.0). The pH of the solution is adjusted to 6.0 with 500mM K₂HPO₄. The sample is applied to an hydroxylapatite column (LKB) equilibrated in 80mM KPO₄, 6M urea (pH6.0) and all unbound protein is removed by washing the column with the same buffer. Bone inductive factor activity is eluted with 100mM KPO₄ (pH7.4) and 6M urea.

[0027] The protein is concentrated approximately 10 times, and solid NaCl added to a final concentration of 0.15M. This material is applied to a heparin - Sepharose column equilibrated in 50mM KPO₄, 150mM NaCl, 6M urea (pH7.4). After extensive washing of the column with starting buffer, a protein with bone inductive factor activity is eluted by 50mM KPO₄, 700mM NaCl, 6M urea (pH7.4). This fraction is concentrated to a minimum volume, and 0.4ml aliquots are applied to Superose 6 and Superose 12 columns connected in series, equilibrated with 4M GuCl, 20mM Tris (pH7.2) and the columns developed at a flow rate of 0.25ml/min. The protein demonstrating bone inductive factor activity has a relative migration corresponding to approximately 30,000 dalton protein.

[0028] The above fractions are pooled, dialyzed against 50mM NaAc, 6M urea (pH4.6), and applied to a Pharmacia MonoS HR column. The column is developed with a gradient to 1.0M NaCl, 50mM NaAc, 6M urea (pH4.6). Active fractions are pooled and brought to pH3.0 with 10% trifluoroacetic acid (TFA). The material is applied to a 0.46 x 25cm Vydac C4 column in 0.1% TFA and the column developed with a gradient to 90% acetonitrile, 0.1% TFA (31.5% acetonitrile, 0.1% TFA to 49.5% acetonitrile, 0.1% TFA in 60 minutes at 1ml per minute). Active material is eluted at approximately 40-44% acetonitrile. Aliquots of the appropriate fractions are iodinated by one of the following methods: P. J. McConahey et al, Int. Arch. Allergy, 29:185-189 (1966); A. E. Bolton et al, Biochem J., 133:529 (1973); and D. F. Bowen-Pope, J. Biol. Chem., 237:5161 (1982). The iodinated proteins present in these fractions are analyzed by SDS gel electrophoresis and urea Triton X 100 isoelectric focusing. At this stage, the bone inductive factor is estimated to be approximately 10-50% pure.

EXAMPLE II

40

55

Characterization of Bovine Bone Inductive Factor

A. Molecular Weight

[0029] Approximately 20ug protein from Example I is lyophilized and redissolved in 1X SDS sample buffer. After 15 minutes of heating at 37°C, the sample is applied to a 15% SDS polyacrylamide gel and then electrophoresed with cooling. The molecular weight is determined relative to prestained molecular weight standards (Bethesda Research Labs). Immediately after completion, the gel lane containing bone inductive factor is sliced into 0.3cm pieces. Each piece is mashed and 1.4ml of 0.1% SDS is added. The samples are shaken gently overnight at room temperature to elute the protein. Each gel slice is desalted to prevent interference in the biological assay. The supernatant from each sample is acidified to pH 3.0 with 10% TFA, filtered through a 0.45 micron membrane and loaded on a 0.46cm x 5cm C4 Vydac column developed with a gradient of 0.1% TFA to 0.1% TFA, 90% CH₃CN. The appropriate bone inductive factor - containing fractions are pooled and reconstituted with 20mg rat matrix. In this gel system, the majority of bone inductive factor fractions have the mobility of a protein having a molecular weight of approximately 28,000 - 30,000 daltons.

B. Isoelectric Focusing

[0030] The isoelectric point of bone inductive factor activity is determined in a denaturing isoelectric focusing system. The Triton X100 urea gel system (Hoeffer Scientific) is modified as follows: 1) 40% of the ampholytes used are Servalyte 3/10; 60% are Servalyte 7-9. 2) The catholyte used is 40mM NaOH. Approximately 20ug of protein from Example I is lyophilized, dissolved in sample buffer and applied to the isoelectrofocusing gel. The gel is run at 20 watts, 10°C for approximately 3 hours. At completion the lane containing bone inductive factor is sliced into 0.5 cm slices. Each piece is mashed in 1.0ml 6M urea, 5mM Tris (pH 7.8) and the samples agitated at room temperature. The samples are acidified, filtered, desalted and assayed as described above. The major portion of activity as determined in the assay described in Example III migrates in a manner consistent with a pl of 8.8 - 9.2.

C. Subunit Characterization

[0031] The subunit composition of bone inductive factor is also determined. Pure bone inductive factor is isolated from a preparative 15% SDS gel as described above. A portion of the sample is then reduced with 5mM DTT in sample buffer and re-electrophoresed on a 15% SDS gel. The approximately 30kd protein yields two major bands at approximately 20kd and 18kd, as well as a minor band at 30kd. The broadness of the two bands indicates heterogeneity caused most probably by glycosylation, other post translational modification, proteolytic degradation or carbamylation.

EXAMPLE III

10

20

Biological Activity of Bone Inductive Factor

[0032] A rat bone formation assay according to the general procedure of Sampath and Reddi, <u>Proc. Natl. Acad. Sci. U.S.A.</u>, 80:6591-6595 (1983) is used to evaluate the osteogenic activity of the bovine bone inductive factor of the present invention obtained in Example I. This assay can also be used to evaluate bone inductive factors of other species. The ethanol precipitation step is replaced by dialyzing the fraction to be assayed against water. The solution or suspension is then redissolved in a volatile solvent, e.g. 0.1 - 0.2 % TFA, and the resulting solution added to 20mg of rat matrix. This material is frozen and lyophilized and the resulting powder enclosed in #5 gelatin capsules. The capsules are implanted subcutaneously in the abdominal thoracic area of 21 - 49 day old male long Evans rats. The implants are removed after 7-14 days. Half of each implant is used for alkaline phosphatase analysis [See, A. H. Reddi et al., <u>Proc. Natl Acad Sci.</u>, 69:1601 (1972)] and half is fixed and processed for histological analysis. Routinely, lum glycolmethacrylate sections are stained with Von Kossa and acid fuschin to detect new bone mineral. Alkaline phosphatase, an enzyme produced by chondroblasts and osteoblasts in the process of matrix formation, is also measured. New cartilage and bone formation often correlates with alkaline phosphatase levels. Table I below illustrates the dose response of the rat matrix samples including a control not treated with bone inductive factor.

TABLE 1

Protein* Implanted ug	Cartilage	Alk. Phos.u/l
7.5	2	Not done
2.5	3	445.7
0.83	3	77.4
0.28	0	32.5
0.00	0	31.0

*At this stage the bone inductive factor is approximately 10-15% pure.

[0033] The bone or cartilage formed is physically confined to the space occupied by the matrix. Samples are also analyzed by SDS gel electrophoresis and isoelectric focusing as described above, followed by autoradiography. Analysis reveals a correlation of activity with protein bands at 28 - 30kd and a pt 9.0. An extinction coefficient of 1 OD/mgcm is used as an estimate for protein and approximating the purity of bone inductive factor in a particular fraction. In the <u>in vivo</u> rat bone formation assays on dilutions as described above, the protein is active <u>in vivo</u> at 10 to 200ng protein/gram bone to probably greater than lug protein/gram bone.

55

50

40

EXAMPLE IV

10

30

45

50

Bovine Bone Inductive Factor Protein Composition

[0034] The protein composition of Example IIA of molecular weight 28 - 30kd is reduced as described in Example IIC and digested with trypsin. Eight tryptic fragments are isolated by standard procedures having the following amino acid sequences:

Fragment 1: A A F L G D I A L D E E D L G

Fragment 2: A F Q V Q Q A A D L

Fragment 3: N Y Q D M V V E G

Fragment 4: STPAQDVSR

Fragment 5: NQEALR

Fragment 6: LSEPDPSHTLEE

15 Fragment 7: F D A Y Y

Fragment 8: LKPSN?ATIQSIVE

[0035] A less highly purified preparation of protein from bovine bone is prepared according to a purification scheme similar to that described in Example I. The purification basically varies from that previously described by omission of the DE-52 column, the CM cellulose column and the mono S column, as well as a reversal in the order of the hydroxylapatite and heparin sepharose columns. Briefly, the concentred crude 4 M extract is brought to 85% final concentration of ethanol at 4 degrees. The mixture is then centrifuged, and the precipitate redissolved in 50 mM Tris, 0.15 M NaCl, 6.0 M urea. This material is then fractionated on Heparin Sepharose as described. The Heparin bound material is fractionated on hydroxyapatite as described. The active fractions are pooled, concentrated, and fractionated on a high resolution gel filtration (TSK 30000 in 6 M guanidinium chloride, 50 mM Tris, pH 7.2). The active fractions are pooled, dialyzed against 0.1% TFA, and then fractionated on a C4 Vydac reverse phase column as described. The preparation is reduced and electrophoresed on an acrylamide gel. The protein corresponding to the 18K band is eluted and digested with trypsin. Tryptic fragments are isolated having the following amino acid sequences:

Fragment 9: S L K P S N H A T I Q S ? V Fragment 10: S F D A Y Y C S ? A

Fragment 11: VYPNMTVESCA

Fragment 12: V D F A D I ? W

35 [0036] Tryptic Fragments 7 and 8 are noted to be substantially the same as Fragments 10 and 9, respectively.

A. bBMP-3

[0037] Probes consisting of pools of oligonucleotides are designed on the basis of the amino acid sequences of the tryptic Fragments 9 (Probe #3), 10 (Probe #2), and 11 (Probe #1), and synthesized on an automated DNA synthesizer.

Probe #1: A C N G T C A T [A/G] T T N G G [A/G] T A

Probe #2: C A [A/G] T A [A/G] T A N G C [A/G] T C [A/G] A A

Probe #3: T G [A/G/T] A T N G T N G C [A/G] T G [A/G] T T

[0038] A bovine genomic recombinant library is constructed as follows: Bovine liver DNA is partially digested with the restriction endonuclease enzyme Sau 3A and sedimented through a sucrose gradient. Size fractionated DNA in the range of 15-30kb is then ligated to the bacteriophage Bam HI vector EMBL3 [Frischauf et al, J. Mol. Biol., 170: 827-842 (1983)]. The library is plated at 8000 recombinants per plate. Duplicate nitrocellulose replicas of the plaques are made and amplified according to a modification of the procedure of Woo et al, Proc. Natl. Acad. Sci. USA, 75: 3688-91 (1978).

[0039] This recombinant bovine genomic library constructed in EMBL3 is screened by the TMAC hybridization procedure, i.e. kyloridized in 3M tetramethylammonium chloride (TMAC), 0.1M sodium phosphate pH6.5, 1mM EDTA, 5X

Denhardts, 0.6% SDS, 100ug/ml salmon sperm DNA at 48 degrees C, and washed in 3M TMAC, 50mM Tris pH8.0 at 50 degrees C. These conditions minimize the detection of mismatches to the 17 mer probe pool [see, Wood et al, Proc. Natl. Acad. Sci, U.S.A., 82:1585-1588 (1985)]. 400,000 recombinants are screened in duplicate with Probe #1 which has been labeled with ³²P. All recombinants which hybridized to this probe are replated for secondaries. Triplicate nitrocellulose replicas are made of the secondary plates, and amplified as described. The three sets of filters are hybridized to Probes #1, #2 and #3, again under TMAC conditions. One clone, lambda bP-819, hybridizes to all three probes and is plaque purified and DNA is isolated from a plate lysate. Bacteriophage lambda bP-819 was deposited with the ATCC on June 16, 1987 under accession number 40344. This bP-819 clone encodes the bovine bone growth factor designated bBMP-3.

[0040] The region of bP-819 which hybridizes to Probe #2 is localized and, sequenced. The partial DNA and derived amino acid sequences of this region are shown in Table IVA. The amino acid sequences corresponding to tryptic Fragments 10 and 12 are underlined. The first underlined sequence corresponds to Fragment 12 while the second corresponds to Fragment 10. This region of bP-819, therefore, which hybridizes to Probe #2 encodes at least 111 amino acids. This amino acid sequence is encoded by the DNA sequence from nucleotide #414 through #746.

15

TABLE IV. A.

383 393 403 413 (1) 428 CACCACGAAG COGTCTACOG GOGTCCTTCT GOCTCTGCAG AAC AAT CAG CTT CCT GOG GCA 20 Asn Asn Glu Leu Pro Gly Ala 458 488 443 473 GAA TAT CAG TAC AAG GAG GAT GAA GTA TGG GAG GAG AGG AAG CCT TAC AAG ACT 25 Glu Tyr Gln Tyr Lys Glu Asp Glu Val Trp Glu Glu Arg Lys Pro Tyr Lys Thr 503 518 533 CTT CAG ACT CAG CCC CCT GAT AAG AGT AAG AAC AAA AAG AAA CAG AGG AAG GGA Leu Gln Thr Gln Pro Pro Asp Lys Ser Lys Asn Lys Lys Lys Gln Arg Lys Gly 30 563 578 CCT CAG CAG AAG AGT CAG ACG CTC CAG TTT GAT GAA CAG ACC CTG AAG AAG GCA Pro Gln Gln Lys Ser Gln Thr Leu Gln Phe Asp Glu Gln Thr Leu Lys Lys Ala 35 608 623 AGA AGA AAG CAA TGG ATT GAA CCC CGG AAT TGT GCC AGA CGG TAC CTT AAA GTG Arg Arg Lys Gln Trp Ile Glu Pro Arg Asn Cys Ala Arg Arg Tyr Leu Lys Val 40 gac tive gca gat ait ggc tigg agc gaa tigg ait ait tice coc aag tice tive gat Asp the Ala Asp Ile Gly Trp Ser Glu Trp Ile Ile Ser Pro Lys Ser the Aso 728 756 743 (111) GOO TAT TAC TGC TOO GGA GOG TGC CAG TTC COO ATG COA AAG GTAGOCATTG 45 Ala Tyr Tyr Cys Ser Gly Ala Cys Gln Phe Pro MET Pro Lys 766 776 786 TTTTTTGTCC TGTCCTTCCC ATTTCCATAG

50

[0041] The region of bP-819 which hybridizes to Probe #1 and #3 is localized and sequenced. The partial DNA and derived amino acid sequences of this region are shown in Table IVB. The amino acid sequences corresponding to tryptic Fragments 9 and 11 are underlined. The first underlined sequence corresponds to Fragment 9 while the second underlined sequence corresponds to Fragment 11. The peptide sequence of this region of bP-819 which hybridizes to Probe #1 and #3 is 64 amino acids in length encoded by nucleotide #305 through #493 of Table IVB. The arginine

residue encoded by the AGA triplet is presumed to be the carboxy-terminus of the protein based on the presence of a stop codon (TAA) adjacent to it. The nucleic acid sequence preceding the couplet TC (positions 305-306) is presumed to be an intron (non-coding sequence) based on the presence of a consensus acceptor sequence (i.e. a pyrimidine-rich stretch, TTCTCCCTTTTCGTTCCT, followed by AG) and the presence of a stop rather than a basic residue in the appropriate position of the derived amino acid sequence.

[0042] bBMP-3 is therefore characterized by the DNA and amino acid sequence of Table IV A and Table IV B. The peptide sequence of this clone is 175 amino acids in length and is encoded by the DNA sequence from nucleotide #414 through nucleotide #746 of Table IV A and nucleotide #305 through nucleotide #493 of Table IV B.

10

15

20

25

30

TABLE IV. B.

284 319 294 304 (112)CTAACCTGTG TTCTCCCTTT TCGTTCCTAG TCT TTG AAG CCA TCA AAT CAC GCT ACC Leu Lys Pro Ser Asn His Ala Thr 349 364 379 334 ATC CAG AGT ATA GTG AGA GCT GTG GGG GTC GTC CCT GGA ATC CCC GAG CCT TGC Ile Gln Ser Ile Val Arg Ala Val Gly Val Pro Gly Ile Pro Glu Pro Cys 409 424 439 394 TGT GTG CCA GAA AAG ATG TCC TCA CTC AGC ATC TTA TTC TIT GAT GAA AAC AAG Cys Val Pro Clu Lys MET Ser Ser Leu Ser Ile Leu Phe Phe Asp Glu Asn Lys

454 469 484 (175) AAT GTG GTA CTT AAA GTA TAT CCA AAC ATG ACA GTA GAG TCT TGT GCT TGC AGA ASN Val Val Leu Lys <u>Val Tyr Pro Asn MET Thr Val Glu Ser Cys Ala</u> Cys Arg

503 513 523 533
TAACCTGGTG AAGAACTCAT CTGGATGCTT AACTCAATCG

35

EXAMPLE V

Human BMP-3

40

45

[0043] The sequences of BMP-3 as shown in Tables IV A+B have significant homology to the beta (B) and beta (A) subunits of the inhibins. The inhibins are a family of hormones which are presently being investigated for use in contraception. See, A. J. Mason et al, Nature, 318:659-663 (1985). To a lesser extent they are also homologous to Mullerian inhibiting substance (MIS), a testicular glycoprotein that causes regression of the Mullerian duct during development of the male embryo and transforming growth factor-beta (TGF-b) which can inhibit or stimulate growth of cells or cause them to differentiate.

[0044] Because bovine and human bone growth factor genes are presumed to be significantly homologous, oligonucleotide probes which have been shown to hybridize to the bovine DNA sequence of Table IV.A and IV.B are used to screen a human genomic library. A human genomic library (Toole et al.; <u>supra</u>) is screened using these probes, and presumptive positives are isolated and DNA sequence obtained as described above. Evidence that this recombinant encodes a portion of the human bone inductive factor molecule relies on the bovine/human protein and gene structure homologies.

[0045] Once a recombinant bacteriophage containing DNA encoding a portion of the human BMP-3 molecule is obtained the human coding sequence is used as a probe as described in Example V (A) to identify a human cell line or tissue which synthesizes BMP-3. mRNA is selected by oligo (dT) cellulose chromatography and cDNA is synthesized and cloned in lambda gt10 by established techniques (Toole et al., supra).

[0046] Alternatively, the entire gene encoding this human bone inductive factor can be identified and obtained in additional recombinant clones if necessary. Additional recombinants containing further 3' or 5' regions of this human

bone inductive factor gene can be obtained by identifying unique DNA sequences at the end(s) of the original clone and using these as probes to rescreen the human genomic library. The gene can then be reassembled in a single plasmid by standard molecular biology techniques and amplified in bacteria. The entire human BMP-3 factor gene can then be transferred to an appropriate expression vector. The expression vector containing the gene is then transfected into a mammalian cell, e.g. monkey COS cells, where the human gene is transcribed and the RNA correctly spliced. Media from the transfected cells are assayed for bone inductive factor activity as described herein as an indication that the gene is complete. mRNA is obtained from these cells and cDNA synthesized from this mRNA source and cloned. The procedures described above may similarly be employed to isolate other species' bone inductive factor of interest by utilizing the bovine bone inductive factor and/or human bone inductive factor as a probe source. Such other species' bone inductive factor may find similar utility in, inter alia, fracture repair.

EXAMPLE VI

10

Expression of Bone Inductive Factors.

[0047] In order to produce bovine, human or other mammalian bone inductive factors, the DNA encoding it is transferred into an appropriate expression vector and introduced into mammalian cells by conventional genetic engineering techniques.

[0048] One skilled in the art can construct mammalian expression vectors by employing the sequence of Tables IV A+B or other modified sequences and known vectors, such as pCD [Okayama et al., Mol. Cell Biol., 2:161-170 (1982)] and pJL3, pJL4 [Gough et al., EMBO J., 4:645-653 (1985)]. The transformation of these vectors into appropriate host cells can result in expression of osteoinductive factors. One skilled in the art could manipulate the sequences of Tables IV A+B by eliminating or replacing the mammalian regulatory sequences flanking the coding sequence with bacterial sequences to create bacterial vectors for intracellular or extracellular expression by bacterial cells. For example, the coding sequences could be further manipulated (e.g., ligated to other known linkers or modified by deleting non-coding sequences there-from or altering nucleotides therein by other known techniques). The modified bone inductive factor coding sequence could then be inserted into a known bacterial vector using procedures such as described in T. Taniguchi et al., Proc. Natl Acad. Sci. USA, 77:5230-5233 (1980). This exemplary bacterial vector could then be transformed into bacterial host cells and bone inductive factor expressed thereby. For a strategy for producing extracellular expression of bone inductive factor in bacterial cells., see, e.g. European patent application EPA 177,343.

[0049] Similar manipulations can be performed for the construction of an insect vector [See, e.g. procedures described in published European patent application 155,476] for expression in insect cells. A yeast vector could also be constructed employing yeast regulatory sequences for intracellular or extracellular expression of the factors of the present invention by yeast cells. [See, e.g., procedures described in published PCT application WO86/00639 and European patent application EPA 123,289].

[0050] A method for producing high levels of an osteoinductive factor of the invention from mammalian cells involves the construction of cells containing multiple copies of the heterologous bone inductive factor gene. The heterologous gene can be linked to an amplifiable marker, e.g. the dihydrofolate reductase (DHFR) gene for which cells containing increased gene copies can be selected for propagation in increasing concentrations of methotrexate (MTX) according to the procedures of Kaufman and Sharp, J. Mol. Biol., 159:601-629 (1982). This approach can be employed with a number of different cell types.

[0051] For example, a plasmid containing a DNA sequence for a bone inductive factor of the invention in operative association with other plasmid sequences enabling expression thereof and the DHFR expression plasmid pAdA26SV (A)3 [Kaufman and Sharp, Mol. Cell. Biol., 2:1304 (1982)] can be co-introduced into DHFR-deficient CHO cells, DUKX-BII, by calcium phosphate coprecipitation and transfection. DHFR expressing transformants are selected for growth in alpha media with dialyzed fetal calf serum, and subsequently selected for amplification by growth in increasing concentrations of MTX (sequential steps in 0.02, 0.2, 1.0 and 5uM MTX) as described in Kaufman et al., Mol Cell Biol., 5:1750 (1983). Transformants are cloned, and biologically active bone inductive factor expression is monitored by rat bone formation assay. Bone inductive factor expression should increase with increasing levels of MTX resistance. Similar procedures can be followed to produce other bone inductive factors.

[0052] Alternatively, the human gene is expressed directly, as described above. Active bone inductive factor may be produced in bacteria or yeast cells. However the presently preferred expression system for biologically active recombinant human bone inductive factor is stably transformed CHO cells.

Example VII

Biological Activity of Expressed Bone Inductive Factor

- [0053] To measure the biological activity of the expressed bone inductive factor obtained in Example VI above. The factor is partially purified on a Heparin Sepharose column. 4 ml of transfection supernatant from one 100 mm dish is concentrated approximately 10 fold by ultrafiltration on a YM 10 membrane and then dialyzed against 20mM Tris, 0.15 M NaCl, pH 7.4 (starting buffer). This material is then applied to a 1.1 ml Heparin Sepharose column in starting buffer. Unbound proteins are removed by an 8 ml wash of starting buffer, and bound proteins are desorbed by a 3-4 ml wash of 20 mM Tris, 2.0 M NaCl, pH 7.4.
 - [0054] The proteins bound by the Heparin column are concentrated approximately 10-fold on a Centricon 10 and the salt reduced by diafiltration with 0.1% trifluoroacetic acid. The appropriate amount of this solution is mixed with 20 mg of rat matrix and then assayed for in vivo bone and cartilage formation as previously described in Example III. A mock transfection supernatant fractionation is used as a control.
- [0055] The implants containing rat matrix to which specific amounts of human BMP-3 have been added are removed from rats after seven days and processed for histological evaluation. Representative sections from each implant are stained for the presence of new bone mineral with von Kossa and acid fuschin, and for the presence of cartilagespecific matrix formation using toluidine blue. The types of cells present within the section, as well as the extent to which these cells display phenotype are evaluated.
- [0056] The procedures described above may be employed to isolate other bone inductive factors of interest by utilizing the bovine bone inductive factors and/or human bone inductive factors as a probe source. Such other bone inductive factors may find similar utility in, inter alia, fracture repair.
- 25 Claims

35

40

45

50

55

Claims for the following Contracting States: BE, CH, LI, DE, FR, GB, IT, LU, NL, SE

30 1. A gene encoding bovine BMP-3 comprising the following DNA sequence:

5	ಎಲಾಎ	28C 2445	œŝi		33 35 64	:GTC	40: ETTC:		IICI	413 3CAG	المد	C AAC n Asi	r Gl	ı Le	42: E CC. L Per	r GGC	i ecy	
	CAA TA Glu Tyr		TAC					GEA										
10	CTT CH																	
15	548 CCT CA Pro Cl:	3 C2G																
20	AGA AGI ATG ATT																	
25	والم المن المن المن المن المن المن المن المن المن المن المن المن			ATT														
	CCC THE	ב עלב	CÀ2 ICC	Ser	€ĵÀ	ccs Alz	723 TGC Cys	CAG Gln	TIC Fhe	000 F23	aig Met _.	743 CCA P20	lýs Lýs	GEAC		756 TTG T	TTTT	766 GICC
30	TETECT		ATTTC		is ;.	ಪಾಣೆ			•									
35	CIPACC	284 ICIG '	TTCIC			ZITT(304 CEPC	T		an Ti		11 22 TC 32 CT	A A		is Al			•
40	334 MC CA Ile Gli	n Ser	<u>Tl</u> e				<u>V21</u>					GJÅ					Cñ2	
45	TGT GR Cys Va		CYY															

2. A gene encoding bovine BMP-3 having the amino acid sequence given in claim 1.

- 3. A gene encoding a protein exhibiting at least the property of BMP-3 to indues the formation of bone and comprising a DNA sequence:
 - (a) which differs from a DNA sequence of claim 1 in codon sequence due to the degeneracy of the genetic code;
 - (b) which hybridizes with a DNA sequence of claim 1 or section (a), above, under stringent hybridization conditions; or
 - (c) which represents a fragment, or allelic variation of a DNA sequence of claim. 1.

5	HT OT (HT VL)	TA CIT Vài Lau	322	GIA.	TYT TYT	\cong	AAC	469 AIG MET	ACA Tair	ota Val	<i>6]:1</i> 6:6	ICI Ser	161 Cys Cys	GCT Ale	TGC Cys	aca Arg
	50 TACCTGG	og aaga. To aaga.	51 ACTC			521 PGCT				•		·				

10

- 4. The DNA sequence of claim 3, which encodes human BMP-3.
- 5. The DNA sequence of claim 3 or 4, which is a genomic DNA sequence.
- 15 6. The DNA sequence of claim 3 or 4, which is a cDNA sequence.
 - A vector containing the gene or DNA sequence of any one of claims 1 to 6 in operative association with an expression control sequence.
- 20 8. A cell transformed with a vector of claim 7.
 - 9. The cell of claim 8 which is a mammalian cell, a bacterial cell, an insect cell or a yeast cell.
 - 10. The cell of claim 9 which is a CHO cell.

25

30

- 11. A protein exhibiting properties of BMP-3 which is encoded by the gene or DNA sequence of any one of claims 1 to 6.
- 12. A protein exhibiting properties of BMP-3 which is produced by the steps of culturing in a suitable culture medium a cell transformed with an expression vector comprising a gene or a DNA sequence of any one of claims 1 to 6, and recovering said protein from said culture medium.
 - 13. A process for producing the protein of claim 11 or 12, comprising the steps of culturing in a suitable culture medium the cell of claim 9 and isolating said protein from said culture medium.
- 35 14. A pharmaceutical composition comprising the protein of claim 11 or 12 and a pharmaceutically acceptable vehicle.
 - 15. The pharmaceutical composition of Claim 14, further comprising a matrix capable of delivering the composition to the site of the bone or cartilage defect and providing a structure for inducing bone or cartilage formation.
- 40 16. The pharmaceutical composition of claim 15, wherein said matrix comprises hydroxyapatite, collagen, polylactic acid or tricalcium phosphate.
 - 17. Use of a protein of claim 11 or 12 for the preparation of a pharmaceutical composition for inducing bone or cartilage formation.

45

Claims for the following Contracting State: AT

1. A method for the preparation of a gene encoding bovine BMP-3 comprising the following DNA sequence:

50

				•												
		383	٠ ٦	93	40	٦.		413					42	2		
											- c.					
	ಆರಾವ	ت عقق	CTCT20	برجيجي جيما	CT-1-1-	T. C.	CTCT	سندس		زحرنر ب	7. 6-7	- C7.	T. CC	. (~	ب ري	.
									عد	7 YE	n GL:	ı Le	u Pr	c Gl'	y Ala	
5												_			•	
		443			458					473					488	
	GAA TRI	CEG	הבנ אמר	626 62	7 622	5	TG	COC	(:)(:	266	346	CCIT	770	220	200	
	Glu Tyr	GLA :	iyr Lys	CIU PS	a eta	<u>15</u> V	.Ti	GIU	CTG	WAG	TÃ2	720	īyī	Lys	1111	
10			503				518					533				
10															_	
	CIT CAG	CICK	ಯ ಎಪ	CCI GA	T 776	æ	286	AAC		aas	AAA	C÷G	acg	æ	<u>ಆವ್ರ</u>	
	ieu Gla	م حنول	نتخر دو:	55 55	57.5	62-	TVS	247	7.55	I Jis	IV=	Gln	3	Tare	GIV	
					5 -2 -3					<u></u> :-	-2-			~, ~		
					•											•
	548			· 56	3				578					593		
	CCT CFG	CAG 3	יובר בביו	CGC 30		Cic	بالملك	CIT	G2 i	35	300	-	226	2.2/2	CO	
15																
	<u> ಶಿಕಾ ಆಗಿಗ</u>	GTY I	ys ser	CIU III	<u>- 1eu</u>	GIU	Pne	وكخ	GTI	GT	The	T\$U	Lys	Ŀys	<u>11</u> 4.	
											٠.		•-	_		
	•		308	. •		623		•			638					
	aga aga	. A.R.G (ra Teg	ATT GR	∞	ಯ	rac.	TGI	α	$\lambda \subseteq \lambda$	æ	TP.C	\mathbf{crr}	AAA	CIG.	
	Arg Arg	LVS C	177 7	Ila Ch	टार्च १	2त्य	250	Cvs	Ala	تتذ	Àr u	\mathcal{D}^{∞}	Teu	7.0%	Va 1	
20	33	. – <u>.</u> – •						-3-		=.	=			-2.0.	-	
20					•											
	653			658				683					693			
	eac TTC	GCA G	27 277	GGC TG	1 200	622	77.7	J. J	544		CCC	220	منب		C2T	
																•
	Asp Rite	برعيم	rzb trs	CTA JE	o ser	CT.	JZD.	775	TTE	252	220	TĀZ	Ser	<i>₹</i> 7.00	ججن	
	:						•									
		713		•	723					743	•		7	35		756
25	coo															
	CCC THI											مكنتا	سيس	IG I	TITI	. <u>53</u> 00~
	Ala Tyr	ی⊼ت د	ys Ser	Gly Ala	2 Cys	حلت	2770	550	NET.	حتج	Lys					
	_	_	-	_	_						•		•			
		776	•													· •.
		–		36			•			•						
	TETCCTI	∞ M	TOTAL	S ; er	2											
30																
		•													•	
					•					_						
		284	25) 4	304	i				31	9					
	رست د دست	من ترت					- 	٠. ب <i>ې</i>	~ ~			TI (-)		- ·	_	
	CERT	G16 11		i Luch	بكتمك											
						Se	r Le	u Ly	's ≥	ວ Se	<u> </u>	n His	s Al	e In	=	
35			•					-								
	224	•		240		•		7-4								
	334			349	•			354					379			
	aic cae	PET A	ere	AGA GC	GIG :	GGG (GIC	GIC	∞	GEA .	FIC (ಞ (ಚಿತ್ರ ,	ರ್ಮ ,	TGC	
	Ile Gln															
	776 671	عصد ل	<u> ب= ۷ حــٰ</u>	ملم وحد	نه ۷ حن	GTĀ	٧ڪڏ	بلت ۷	7.3	GTĀ	<u> </u>	\	3 <u>11</u>	220	C.12	
			•													
		394			409					424					470	
40	:														439	•
	ici ele															
	Cys Val	Pro G	lu Lvs	MET Ser	Ser	Leu :	Ser	Tle	Leu	Fhe.	ene i	<u>نحد</u>	Glu.	ا يوخ	Lvs	
	-1	-													- <u>,</u> -	

2. The method of claim 1, wherein the gene encoding the BMP-3 has the amino acid sequence given in claim 1.

50

- 3. The method of claim 1, wherein a gene encoding a protein exhibiting at least the property of BMP-3 to induce the formation of bone comprises a DNA sequence:
- (a) which differs from a DNA sequence obtained according to the method of claim 1 in codon sequence due to the degeneracy of the genetic code;
 - (b) which hybridises with a DNA sequence obtained according to the method of claim 1 or section (a), above under stringent hybridisation conditions; or
 - (c) which represents a fragment, or allelic variation of a DNA sequence obtained according to the method of claim 1.

469 454 We also also cle the test and the pre per see the sale and the per per per per Ass Val Val Lou Lys Val Tyr Pro Ass MET The Val Glu Ser Cys Ala Cys Arg 533 523 503 TACCINGIG AAGAACICAI CIG said method comprising screening of a recombinant bovine genomic library with probes consisting of pools of oligonucleotides designed on the basis of partial amino acid sequences and isolating a positive clone. 4. The method of claim 3, wherein the DNA sequence encodes human BMP-3. 5. The method of claim 3 or 4, wherein the DNA sequence is a genomic DNA sequence. 6. The method of claim 3 or 4, wherein the DNA sequence is a cDNA sequence. 7. A method for the preparation of a recombinant vector comprising inserting the gene or DNA sequence obtained according to a method of any one of claims 1 to 6 in operative association with an expression control sequence in a suitable vector. 8. A cell transformed with a vector prepared according to the method of claim 7. 9. The cell of claim 8 which is a mammalian cell, a bacterial cell, an insect cell or a yeast cell. 10. The cell of claim 9 which is a CHO cell. 11. A process for producing a protein exhibiting properties of BMP-3 comprising the steps of culturing in a suitable culture medium the cell of claim 9 and isolating said protein from said culture medium. 12. A method for the preparation of a pharmaceutical composition comprising combining the protein produced according to the method of claim 11 with a pharmaceutically acceptable vehicle. 13. The method of claim 12, wherein the pharmaceutical composition further comprises a matrix capable of delivering the composition to the site of the bone or cartilage defect and providing a structure for inducing bone or cartilage formation. 14. The method of claim 13, wherein said matrix of said pharmaceutical composition comprises hydroxyapatite, collagen, polylactic acid or tricalcium phosphate. 15. Use of a protein of claim 11 for the preparation of a pharmaceutical composition for inducing bone or cartilage formation. 16. A gene encoding bovine BMP-3 comprising the following DNA sequence:

10

15

20

25

35

40

45

50

55

5	(SC ಎಸಲಾನಾವಾ	ಯುದ್ರಾಯ ಅಲ್ಲಾದ 393	403 413 TTICT CCCICTGC46	YEU YEU GIN TEN ELD GIÅ YTS YYC YYL GIR CLL CCL CCC CCY 759
10		TAC AAG GAG GAT		473 . 488 Cas ass add cot tac am act Glu arg Lys Ard Tyr Lys Tar
				511 AAA AAG AAA CAG AGG AAG GGA Lys Lys Cly Aly Lys Gly
15				576 GAA CAG ACC CTG AAG AAG GCA Glu Gln Thr Lau Lys Lys Ala
20				ens are the cut and ene end have the life had als are the life had
05	Asp She Ala	لتن Tie Clà تعر	Ser Clu Im. Ile	ATT TOO COO AAS TOO THO GAT The Ser Pro Lys Ser Phe Asp
25	He Lit Lit	TGC TGC GGA GGG Cys Ser Gly Ala	728 TGC CAG TTC CCC Cys Gln Fire Fro	743 755 766 ANG COL ALG COLCOLOGY THITTHENCE- MET Pro Lys
30		786 ATTICATAS ; and		~
: 35 .			Ser leu Ly	319 G CCA TCA ANT CAC GCT ACC S Papo Ser Asia His Ale Ting
				379 CCI GGA AIC CCC GAS CCI TEC Pro Gly Ile Pro Glu Pro Cys
40		GAR ARE ATC TOO		424 TEA TIC TIT GAT GAA AAC AAG Leu Fne Phe Asp Glu Asm Lys

45 17. A gene encoding bovine BMP-3 having the amino acid sequence given in claim 16.

50

55

- 18. A gene encoding a protein exhibiting at least the property of BMP-3 to induce the formation of bone and comprising a DNA sequence:
 - (a) which differs from a DNA sequence of claim 16 in codon sequence due to the degeneracy of the genetic code;
 - (b) which hybridises with a DNA sequence of claim 16 or section (a), above, under stringent hybridisation conditions; or
 - (c) which represents a fragment, or allelic variation of a DNA sequence of claim 16.

5	he as as he	454 CTT AAA GTA TA Leu Lys Val Ty	7 ~2 220 2	76 AG EI	a eac scr 1 Glu ser	CAR YTS ACE COE 484	Cis yed Cos yed
	503 Tacciccic a	PÉPYCLCYL CLEG PÉPYCLCYL CLEG	523 AIGCIT AACI	533 Cratce.			

10

- 19. The DNA sequence of claim 18, which encodes human BMP-3.
- 20. The DNA sequence of claim 18 or 19, which is a genomic DNA sequence.
- 21. The DNA sequence of claim 18 or 19, which is a cDNA sequence.
 - 22. A vector containing the gene or DNA sequence of any one of claims 16 to 21 in operative association with an expression control sequence.
- 20 23. A cell transformed with a vector of claim 22.
 - 24. The cell of claim 23 which is a mammalian cell, a bacterial cell, an insect cell or a yeast cell.
 - 25. The cell of claim 24, which is a CHO cell.

25

- 26. A protein exhibiting properties of BMP-3 which is encoded by the gene or DNA sequence of any one of claims 1 to 21.
- 27. A protein exhibiting properties of BMP-3 which is produced by the steps of culturing in a suitable culture medium a cell transformed with an expression vector comprising a gene or a DNA sequence of any one of claims 1 to 21 and recovering said protein from said culture medium.
 - 28. A pharmaceutical composition comprising the protein of claim 26 or 27 and a pharmaceutically acceptable vehicle.
- 29. The pharmaceutical composition of claim 29, further comprising a matrix capable of delivering the composition to the site of the bone or cartilage defect and providing a structure for inducing bone or cartilage formation.
 - **30.** The pharmaceutical composition of claim 29, wherein said matrix comprises hydroxyapatite, collagen, polylactic acid or tricalcium phosphate.

40

Patentansprüche

- Patentansprüche für folgende Vertragsstaaten : BE, CH, LI, DE, FR, GB, IT, LU, NL, SE
 - 1. Gen, das bovines BMP-3 codiert, welches die folgende DNA-Sequenz umfasst:

50

	36	:3	393	403	413		÷23	
	٩	و صفاحة	ಕ್ಷದ್ದಂ ಆಡುವ	ಹಾಡ ಯ			ತ್ತು ಬ್ರಾಮ	
					کيد	n Asn Glu La	n 350 GJÀ YJS	
5		443		458		473 .	488	
						hee has con		
	ejn iši e	ar da ri	نع ور به پخت	GIU VEI	Tro Glu Glu	yrd fñe yro	iàr tàr inr	
		50) 3		513	533	,	
10						AAG AAA CAG		
	ien eju i	ing Gla R	ಡ್ ಚಿತ್ರಾ	The Sec	Iys Asa Iys	The The Clu	ynd gŵn eTà	
	548		· 563	•	578		5 5 3	
	ಯಾ ಆಕ ರ		er are has		tit et el	TOPE ACC CITE	ANG ANG GCA	
15	ಚಾ ಲಾ ಆ	in iys Se	e Cla The	leu Gla	We yab ejn	Gln Tir Leu	īña īña 175	
		608	•	623	·-·	638		
						AGA CG TAC		
	भाव भाव प्र	ñe eta II	is The Clu	े ट्रिक स्टिय	yan cha yys	yad yad ila	isu iya ,vai	
20	653		668		5 83		653	
						ವಿಷ್ಣ ಯಾ ಸಿಕಿಕ ನಿರ್ಮ		
	yza zus y	נו בבא בוי	's età axò	zez cin .	Isb. ITS ITS	Ser Fro Lys	Ser She Yab	
		713	•	723		743	755	766
25	COC THE T	BL TGC TO	22 CON 122	TGC CAG	TTC CCC ATG	CCY YMG GEN	CCATE TEXT	<u> </u>
	PTS IAL I	TAT CAR 26	E GTA WTS	CAR GTU	The Pro KET	FED TAR	•	
	77		786			•		
	TETECTIC	x arra	IRG; and			•		
30		•		•			•	
	28		294	304		319		•
	CIPACCIGI	ie ricici	RIF TOTAL			r tor art o		
		•	•	34.	s red rive as	n Ser Asa Hi		
35	334		349	·	354		379	
	ATC CRE'A	er er er	TO AGA GCT	ट्यट ट्टिट (लंट लंट व्य	GGA ATC CCC	दस्द ट्या खट	
	THE CTU 2	er ile ve	ल अस्तु अस्ट	AST GIA	رج رج کے	Gly Ile 200	eta eta cire	3 .
	. 3	394	٠	409		424	439	
40						TIC TIT GAT		
	CÃE AST E	szo. etn ti	s Mer Ser	Set Leu S	Ser Ile Leu	the the ksp	Clu yeu lys	
		45			469	484		
	and the contract of	er cee aa	a cora trati	€ 344 £	ATG ACR GER	क्ट रूटा रूटा	ल्या तस्य १८५४	
45	AST VEL V	st ten tå	2 157	و تحور دود	en en vir	Glu Ser Cia	yrs Cla ynd	.:
	503	3	513	523	533	•		
	PACTIGI	g aagaact	ರಾ ದಾಯಾ					
50								

- 2. Gen, das bovines BMP-3 codiert, welches die Aminosäuresequenz aufweist, die in Anspruch 1 angegeben ist.
- Gen, das ein Protein codiert, das mindestens die Eigenschaft von BMP-3 aufweist, die Bildung von Knochen zu induzieren, und eine DNA-Sequenz umfasst:
 - (a) die sich von einer DNA-Sequenz nach Anspruch 1 in der Codonsequenz auf Grund der Degeneriertheit des genetischen Codes unterscheidet;

- (b) die mit einer DNA-Sequenz nach Anspruch 1 oder Absatz (a) oben unter stringenten Hybridisierungsbedingungen hybridisiert; oder
- (c) die ein Fragment oder eine allelische Variation einer DNA-Sequenz nach Anspruch 1 darstellt.
- 5 4. DNA-Sequenz nach Anspruch 3, die menschliches BMP-3 codiert.
 - 5. DNA-Sequenz nach Anspruch 3 oder 4, die eine genomische DNA-Sequenz ist.
 - 6. DNA-Sequenz nach Anspruch 3 oder 4, die eine cDNA-Sequenz ist.

7. Vektor, der das Gen oder die DNA-Sequenz nach einem der Ansprüche 1 bis 6 in funktioneller Verknüpfung mit einer Expressionskontrollsequenz enthält.

- 8. Zelle, transformiert mit einem Vektor nach Anspruch 7.
- 9. Zelle nach Anspruch 8, die eine Säugerzelle, eine Bakterienzelle, eine Insektenzelle oder eine Hefezelle ist.
- 10. Zelle nach Anspruch 9, die eine CHO-Zelle ist.

10

15

25

30

35

45

50

55

- 20 11. Protein, das Eigenschaften von BMP-3 aufweist, das von dem Gen oder der DNA-Sequenz nach einem der Ansprüche 1 bis 6 codiert wird.
 - 12. Protein, das Eigenschaften von BMP-3 aufweist, das durch die Schritte des Züchtens in einem geeigneten Kulturmedium von einer Zelle, die mit einem Expressionsvektor transformiert ist, der ein Gen oder eine DNA-Sequenz nach einem der Ansprüche 1 bis 6 umfasst, und des Gewinnens des Proteins aus dem Kulturmedium hergestellt wird.
 - 13. Verfahren zur Herstellung des Proteins nach Anspruch 11 oder 12, umfassend die Schritte des Züchtens der Zelle nach Anspruch 9 in einem geeigneten Kulturmedium und des Isolierens des Proteins aus dem Kulturmedium.
 - 14. Arzneimittel, umfassend das Protein nach Anspruch 11 oder 12 und ein pharmazeutisch verträgliches Vehikel.
 - 15. Arzneimittel nach Anspruch 14, das zusätzlich eine Matrix umfasst, die das Mittel an die Stelle des Knochen- oder Knorpeldefekts bringen und eine Struktur zum Induzieren von Knochen- oder Knorpelbildung zur Verfügung stellen kann.
 - Arzneimittel nach Anspruch 15, wobei die Matrix Hydroxyapatit, Kollagen, Polymilchsäure oder Tricalciumphosphat umfasst.
- 40 17. Verwendung eines Proteins nach Anspruch 11 öder 12 für die Herstellung eines Arzneimittels zum Induzieren von Knochen- oder Knorpelbildung.

Patentansprüche für folgenden Vertragsstaat : AT

1. Verfahren zur Herstellung eines Gens, das bovines BMP-3 codiert, welches die folgende DNA-Sequenz umfasst:

GREGORIAGO GRECURADO GRETOCITOT GRETICOLOS ANO ANT GAS OTT CIT GREE CON ASTA AND GAS LEE PTO GLY ALE 443 458 477 487 688 686 687 684 684 685 AGE AND GAT TAC AND ACT THE AND ACT GLU TYP GAS THE GAS GAS GAS AND GAT TAC AND ACT GLU TYP GAS THE LYS GLY AND ALE AND AND AND CAS AND GAS AND ACT GAS ACT GAS ACT GAS AND GAS AND		282	393	403	413	425
### 443			ಡ್ಡಾದ್ಯಾಡ್ ಆಡ	TOTTOT GOOTO	rccas - aac aar c	क्ष्य त्या त्या त्या त्या
443 443 443 443 444 445 640 477 610 677 678 678 678 678 678 678 678 678 678					Asa Asa G	in ten 300 Giå yys
CHU TYT Gần TYT LýS Gầu ÁSP Gầu Vài Trợ Gầu Gầu ÂNG LÝS PHO TYT LÝS THE SOI	5				_	
501 518 533 CIT CAS ACT CAS COC COT GAT ANS ART ANS AND AND AND CAS AND GAD LEU CHI THE GAD FOR DATE LEU SER LYS LYS LYS LYS CHA LYS LYS GAD ACT LYS GAD CAS AND GAD AND LYS LYS LYS LYS LAS AND						
10 CTT CGG ACT CGG CCT CGT ANG ACT ANG ANG ANA ANG ANA CGG ANG CGA 10 10 CH THT CHA PRO PRO ASD Mys Ser Mys And Mys Mys Cha Act Mys Cdy 548 CCT CGG CGG ANG ACT CGG ACG CTC CGG TTT CGT CAN CGG ACC CTG ANG ANG CCA 15 PRO CHA CHA Mys Ser Cha The Leu Cha Pre Asp Chu Cha The Leu Mys Mys Ala 608 ACA ANA ANA ANG CGA TGG ACT CGA ACT TGT CGC ACG THE CGT ANA GTG ANG ANA ANA ANG CGA TGG ACT CGA ACT CGG ANT TGT CGC ACG THE CGT TANA GTG ANG ANG ANG ATT CAT CGA ACT CGA ACT CGG ANT TGT CGC ACG THE CGT ANA GTG 653 GCC TTC GCA GCT ATT GGC TGG ACC GGA TGG ACT ACT ACT TGC CGC ANA TGC TTC CGT AND PRE AND AND THE GMY TTP SER CHU THP THE TES SER PRO MYS SER PRE ACP 713 728 659 650 651 652 653 653 653 654 655 656 657 658 658 658 658 658		GIR JAL CTU	I TAL TAR GIG Y	בם פות אבו וב	s end end was thi	e too lat the the
1	10				•	
548 563 563 576 684 685 684 685 684 685 684 684 684 685 684 685 684 685 684 685 684 685 684 685 685 685 685 685 685 685 685 685 685	10					
CTT CGC CMG ANG ACT CGG ACG CTC CAG TITT CGT CAA CGG ACC CTG AMG ANG CGA Pro Clin Gin lys Ser Gin Thr leu Cin Phe Asp Clu Gin Thr Leu Lys Lys Ala 608 ACA AGA CAA TGG ACT CAG ACG CGG ANT TGT CGC AGA CGG TAC CTT TAAA CTG ANG ANG ANG CGA TGG ACG CAG ANT TGT CGC AGA CGG TAC CTT TAAA CTG ANG ANG Lys Gin The lile Giu Seo Ang Ash Coys Ala Ang Ang Tyr Leu Lys Val 653 GCC TTC GGA GCT ACT CGC TGG ACC GAA TGG ACT ACT TCC CGC AAG TGC TTC CGC AAS TGC TTC GGA GGC TGG CAG CGA TGG ACG ACG ACG ACG ACG ACG ACG ACG ACG A		TEN GAN AND	. 611: 510 540 8	an mas ser ma	a van råa råa rå:	s entrand the eth
### 15 Pro Cln Cln Lys Ser Gln Thr Leu Gln The Asp Clu Gln Thr Leu Lys Lys Ala 608 623 633 AGA ANA ANG CA TGG ACT GAA CCC GGG ANT TGT GCC AGA CGG TAC CTT ANA GTG AND AND Lys Gln Trp Lle Glu Pro And Asm Cys Ala Ang Ang Tyr Leu Lys Val 20 653 653 653 GAC TTC GGA GGT ANT 666 TGG ACC GGA TGG AET ANT TGC CCC AAG TGC TTC GGT ASP Pre Ala Asp Ile Gly Trp Ser Glu Trp Ile Ile Ser Pro Lys Ser Pre Asp 713 728 743 755 766 25 GCC THT TAC TGC TGC GGA GGC TGC CGC TTC CCC AAG GTAGCATTG TTTTTTGTCCC- Ala Tyr Tyr Cys Ser Cly Ala Cys Gln Pre Pro NET Pro Lys 776 785 TGTCCTTCCC ATTTCCCTTG TCGTCCTGG TGT TTG AAG CGA AAG GTAGCATTG TTTTTTGTCCC- ATTTCCCTTCC ATTTCCCTTG TCGTCCTGG TGT TTG AAG CGA TGA AAT CAC GGT ACC Ser Leu Lys Pro Ser Asm His Ala Thr 30 284 294 304 319 TGT GGG AGT ATA GGG AGA GGT GGG GGG GGC GGG GGG AATC CGC GAG CGT TGC Tle Gln Ser Ile Val Ang Ala Val Gly Val Val Pro Gly Ile Pro Gly Pro Cys 409 424 409 TGT GGG CGG AGA AAG ATG TGC TGC AGA AAG CTC GAG AAAG AA						
608 623 638 AGA AMA CAA TAG ATG MAT GRA CCC CAG AMT TOT CCC AMA CAG TAG CTT AMA GTG ANG ANG ANG ANG CAT TAG ACC CAG AMT TOT CCC AMA CAG TAG CTT AMA GTG ANG ANG ANG ANG ANG ANG ANG ANG ANG AN	15					
AGA AGA AGG CAR THE ACT CORE AND THE COX AGA COR THE AGA COR THE AGA COR THE AGA COR AGA AGA COR AGA AGA COR AGA COR AGA AGA AGA COR AGA AGA AGA AGA AGA AGA AGA AGA AGA AG	,,,					. me fin min we
Arg Arg Lys Gln Trp Ile Glu Fro Arg Asn Cys Ale Arg Arg Tyr Lei Lys Vel 653 668 683 683 683 GRC TTC GCA GCT ATT GGC TGG AGC GAA TGG ATT ATT TCC CCC AAG TGC TTC GCT Asp File Ale Asp Ile Gly Trp Ser Glu Trp Ile Ile Ser Fro Lys Ser File Asp 711 723 743 755 766 GCC THT TRC TGC TGC GGA GGC TGC CGG TTC CCC ATG CCA AAG GTACCOATTG TTTTTTGTCCC- Ale Tyr Tyr Cys Ser Gly Ale Cys Gln File Fro MTT Fro Lys 776 785 TGTCCTTCCC ATTTCCATAG ; and 284 254 304 119 CTPACCTGG TCC TCC TCC TCC TCC TCC AGC CCT ACC Ser Leu Lys Fro Ser Asn His Ale Tic 35 334 349 154 154 175 ATC CGG MGT MTA GGC MGA GCT GGG GGC GGC GGC GGC GGC GGC GGC GGC		מרו מרו מוכ				
20 653 658 658 653 653 653 GCC TIC GCA GCT MIT GGC TGG MCC GAM TGG MIT MIT TCC CCC MAG TCC TIC GCT MSp Min Min Map The Gly Trip Ser Glu Trip The New Mer Mit Min Grace Mag 711 728 743 755 766 25 GCC TET TAC TGC TGC GGA GGC TGC CAG TCC CCC MIG CCA MAG GENEROLITIG TETETHORICAL Ala Tyr Tyr Cys Ser Gly Min Cys Gln Ene Pro MET Pro Lys 776 785 TGTCCTTCCC MITTCCMTGG ; and 30 284 254 104 119 CTPACCTGG TTCTCCCTT TCCTCCTC TCT TTC MAG CCA TCA MAT CAC GCT MCC Ser Leu Lys Pro Ser Man Min Min Min Min Min Min Min Min Min Mi		Arg Arg Lys	Gla Tap Ile G	lu Pro Arg Asi	n Ove Ale Are Are	The CH had GIG
### THE SET AFT SET THE ARC EAR THE AFT THE THE COL ARC THE SET ARE ARE PER ARE ARE THE THE THE THE THE THE THE THE THE TH	20	•			•	_
Asp She Ale Asp The Gly Trp Ser Glu Trp The The Ser Pro Lys Ser Rhe Asp 713 728 743 755 766 600 TMT TAC TGC GGA GGG TGC GGA TTC GGA AAG GTAGGGATG TTTTTTGTGGA- Ale Tyr Tyr Cys Ser Gly Ale Cys Gln Phe Pro MET Pro Lys 776 785 TGGGGTGGC ATTTGGATAG ; and 284 254 304 319 CTAGGTGG TTGGGGTGT TGGTGGTGG TGT TTG AAG GGA ATC GG GGT ACC Ser Leu Lys Pro Ser Asm His Ale Tur 35 314 349 359 354 377 ACC GGG AGT ATA GGG AGA GGT GGG GGC GGC GGC GGG AGC GGG GGT TGC The Gln Ser The Val Ary Ale Val Chy Val Val Pro Gly The Pro Glu Pro Cys 40 TGT GGG CGA AAG AGG TGC TGC AGC ATC TTA TGC TTG GAA AAG AAG Cys Val Pro Glu Lys HET Ser Ser Leu Ser The Leu Phe Phe Asp Glu Asm Lys 454 455 434 AAT GGG GGA CTT AAA GGA TGT GGA AGG GGA GGG TGC AGG 455 ASM Val Val Leu Lys Val Tyr Pro Asm MET Thr Val Glu Ser Cys Ale Cys Arg 503 513 523 533				56 260 622 70		
25 GCC THE TAC TOC TOC GEA GCC TGC CAG TGC CAG AND GEACCATED THEFTHOLOGY. Als Tyr Tyr Cys Ser Gly Als Cys Gln She Pro MET Pro Lys 776 785 TOTCCTTCCC ATTICCATES; and 284 254 304 119 CTRACTION TECTOCOTTE TOSTCCTES TCT TIC AND CAL TCA ANT CAC GCT ACC Ser Leu Lys Pro Ser Ash His Als The 35 334 349 354 379 ATC CAG ACT ATA GCG ACA GCT GGG GGC GGC GGC GGC ACC GAS ACC CCC GAS CCT TAC The Gln Ser The Val Any Als Val Chy Val Val Pro Gly The Pro Glu Pro Cys 40 TOT GGG CCA GAA ANS AND TCC TCA CCC ACC ACC TTA TGC TTT GAT GAA AND AND Cys Val Pro Glu Lys HET Ser Ser Leu Ser The Leu She Phe Asp Glu Ash Lys 454 455 ANT GGG GGA CTT ANA GTA TAT CCA AND AND ACC GGA GGA GGA GGA CYS Als Cys Ang 503 513 523 533		yab Bus Ma	Asp Ile Gly I	ro Ser Glu Ir	o Ile Ile Ser Fr	Lys Sar The Asp
25 GCC THE TAC TOC TOC GEA GCC TGC CAG TGC CAG AND GEACCATED THEFTHOLOGY. Als Tyr Tyr Cys Ser Gly Als Cys Gln She Pro MET Pro Lys 776 785 TOTCCTTCCC ATTICCATES; and 284 254 304 119 CTRACTION TECTOCOTTE TOSTCCTES TCT TIC AND CAL TCA ANT CAC GCT ACC Ser Leu Lys Pro Ser Ash His Als The 35 334 349 354 379 ATC CAG ACT ATA GCG ACA GCT GGG GGC GGC GGC GGC ACC GAS ACC CCC GAS CCT TAC The Gln Ser The Val Any Als Val Chy Val Val Pro Gly The Pro Glu Pro Cys 40 TOT GGG CCA GAA ANS AND TCC TCA CCC ACC ACC TTA TGC TTT GAT GAA AND AND Cys Val Pro Glu Lys HET Ser Ser Leu Ser The Leu She Phe Asp Glu Ash Lys 454 455 ANT GGG GGA CTT ANA GTA TAT CCA AND AND ACC GGA GGA GGA GGA CYS Als Cys Ang 503 513 523 533		717		772	747	. 755 746
Ala Tyr Tyr Oys Ser Gly Ala Cys Gln Ene Pro MET Pro Lys 776 785 TERCETTOCE ATTREMENS; and 284 254 304 119 CTRACTION TERMINISTING TOT THE AMS COA TOA AMT CAC GOT ACC SER Leu Lys Pro Ser Asm His Ala The 35 334 349 354 379 ATC CAS ANT ATR GIG MAR GOT GIG GGG GIC GIC GGA AMC COC GAS COT TAC The Gln Ser The Val Any Ala Val Chy Val Val Pro Gly The Pro Glu Pro Cys 40 Ter GIG COA GAA AMS AND TOC TOA CIC ACC ANC TER TIC TIT GAT GAA AMC AMC Cys Val Pro Glu Lys MET Ser Ser Leu Ser The Leu Ene Phe Asp Glu Asm Lys 454 455 ANT GIG GIA CIT AMA GIR THE COA AMC ANG ANG GIA GAS TOT TET GOT TOC ACA 455 Asm Val Val Leu Lys Val Tyr Pro Asm MET The Val Glu Ser Cys Ala Cys Ang 503 513 523 533	25	GOC THT THE	TGC TCC GGA G	ಹ ಇದು ದಾವ ಇಗ	בא אבים פיבא ככבו ב	CERCOTTE TITTETOTO-
284 294 304 319 CTRACTION ATTOCKTS : and 284 294 304 319 CTRACTION TECHNOLOGY TOT THE AME ON TON AME CAN GOT AND SET Lett Lys Pro Ser Am His Ale The 35 314 349 354 179 MIC CHE MET MER ONE MAR GOT ONE GOG ONE ONE GAR MIC CON CASE COT THE Tile Gin Ser Tile Val Arg Ale Val Gly Val Val Pro Gly Tile Pro Glu Pro Cys 40 TOT ONE CON GAR AME AND TON TON CON AND THE THE THE GAT GAR AND AME Cys Val Pro Glu Lys MET Ser Ser Lett Ser Tile Lett The Phe Amp Glu Ami Lys AME ONE GIR COT AMA GIR THE CON AND AND AND TON TON GOT TON AND AME CYS Val Val Lett Lys Val Typ Pro Ami MET The Val Glu Ser Cys Ale Cys Arg 503 513 523 533		yys the the	Cys Ser Cly A	la Cys Gln Fre	s fro kal bas frá	,
284 254 304 319 CTPACTION TECHNOLOGY TOWNTOWNS TOT THE AME COA TOA AMT CAC GOT ACC SET Leu Lys Pro Ser Am His Als The 35 334 349 354 379 HIC CAS HET MER GOS MAA GOT GOS GOS GOS GOS GOT GOA MIC COX GAS COT TOC TILE GIN SET ILLE Val Arg Als Val Gly Val Val Pro Gly Ille Pro Glu Pro Cys 40 TOT GOS COA GAA AMS AND TOX TOA COX CAC AND TOX TOX TOX GAA AAC AAC CYS Val Pro Glu Lys MET Ser Sar Leu Ser Ille Leu Phe Phe Asp Glu Am Lys 454 455 454 AMT GOS GOA COT AAA GOA GOA GOA GOA GOA GOA GOA GOA GOA		776	. 785			
284 254 304 319 CTRACTICITE TECHNICIPE TOUTCOME TOT THE AME COA TOA AMT CAC GOT ACC SET LEW LYS PRO SET ASH HIS ALS THE 35 334 349 354 377 ATC CAC AME AME CAC GOT GOT COT GOA AMC COC GAS COT TOC THE GIR SET THE VEL AND ALS VEL GLY VEL VEL PRO GLY THE PRO GLY PRO CYS 40 TOT GIC COA GAA AME ATC TOC TOA COC ACC ATC TEA THO TIT GAT GAA AMC AME CYS VEL PRO GLY LYS MET SET LEW SET THE LEW PRE ASP GLY ASH LYS 45 ASH VEL VEL LEW LYS VEL TYT PRO ASH MET THE VEL GLY SET CYS ALS CYS AND 503 513 523 533		TETCCTTCCC.	ATTICATAS; at	nd.		
Ser Leu Lys Pro Ser Ash His Ale Thr 35 36 37 37 38 39 310 310 310 310 310 310 310	30		•			•
Ser Leu Lys Pro Ser Asm His Ale The 35 36 37 37 38 39 300 300 300 300 300 300		284	254	304	319	
35 314 319 319 310 310 310 3110 3110 3110 3110		anycalete	TICICCCITY TCS.			
MIC CAG ACT ATA CITS HAA CCT CITS CCG CITS CCT CCA ACT CCC CAS CCT TACT THE CHIN Ser Ille Val Ary Ala Val Cly Val Val Pro Cly Ille Pro Clu Pro Cys 109 409 424 419 409 424 419 409 TOT CITS CITS CAA AAC ATC TOC TOC ACC ATC TITS TICS TITS CAT CAA AAC AAC CYS Val Pro Clu Lys Met Ser Ser Leu Ser Ille Leu Phe Phe Asp Clu Ash Lys 454 454 454 455 457 458 458 459 503 513 523 533		•	•	Ser I	ran tha tha bat bat y	שנו פוא צוב הפ
Ile Gin Ser Ile Val Ary Ala Val Giy Val Val Pro Gly Ile Pro Glu Pro Cys 394 409 424 439 439 Ter ore ora GAA AAG ATC TOC TCA CTC ACC ATC TTA TTC TIT GAT GAA AAG AAG Cys Val Pro Glu Lys MET Ser Ser Leu Ser Ile Leu Fhe Phe Asp Glu Asn Lys 454 455 457 458 459 450 450 451 451 452 453 454 AAT GTC GTA CTT AAA GTA TAT CCA AAC ATC ACA GTA GAG TCT TGT GTT TGC ACA ASN Val Val Leu Lys Val Tyr Pro Asn MET Thr Val Glu Ser Cys Ala Cys Ary 503 513 523 533	35					
394 409 424 439 THE GIE CON GAN AME ATE TOO TON CITC ACC ATC TEN TIC THE GAT GAN AND AND CYS Val Pro Glu Lys MET Ser Ser Leu Ser Ile Leu Fhe Phe Asp Glu Asn Lys 454 455 454 ANT GIT GIA CIT ANN GIA THE CON AND ACR GIA GAS TOT TOT GIT TOO ACR 45 Asn Val Val Leu Lys Val Tyr Pro Asn MET The Val Glu Ser Cys Ala Cys Arg 503 513 523 533		ATC CAG AGE	' FIER GIG FER CO	er ere eee ere La val élv val	e ore our oan are	cas ere car are
THE ONE COA GAA AME ATTE TOO TOA ONE AND THE THE THE GAT GAA AME AME OVE VAL PRO GLU LYS MET SAY LAU SAY THE LAU FRA PRO ASS GLU ASS LYS ASS GROWN GAS GAT		116 671 26	·	re ver Grå ver	r AST 322 GTĀ TIB	s and our and cha
Cys Vel Pro Glu Lys MET Ser Ser Leu Ser Ile Leu Fhe Phe Asp Glu Asn Lys 454 459 454 454 455 457 677 677 677 677						
454 455 454 ANT GOT GOTA COTT ANA GOTA OTAT COTA ANC ANG ACA GOTA GAGA TOOT TOO GOTA TOO ANA 45 AREA VALL VALL LEVE LYSE VALL TYPE PRO AREA MOST THAT VALL GLAU SER CYSE ALLA CYSE ANG 503 513 523 533	40					
ANT ONE OF CTT AND OTH THE CTA AND AND ACT OTH ONE TOT TOT OUT THE AND ASS. Val. Val. Lev. Lys. Val. Typ. Sto Ass. MET Thir Val. Glu. Ser. Cys. Alia. Cys. Ang 503 513 523 533		ديء حد ۽ دي			. 112 124 212 212	י איז פור איזי דאָצ
45 Am Val Val Isu iya Val Tyr Suo Am Mer Tur Val Glu Ser Cya Ala Cya Arg 503 513 523 533		110 ~~~				
503 513 523 533	45	Am Val Val	Let Ive Val Tv		r ACA GLA GAL TOT 'Tar Vel Glu Ser	Cas 713 Cas 2000 Cas 713 Cas 2000
	₹•					ele ele ele
الما المراز المر		_				
		الم مالامتيان بالقداد		wienii yydd	يختانه.	
50	50					
50	50					

wobei das Verfahren das Durchmustern einer rekombinanten bovinen genomischen Bibliothek mit Sonden, die aus Pools von Oligonucleotiden bestehen, die auf der Grundlage von partiellen Aminosäuresequenzen hergestellt wurden, und das Isolieren eines positiven Klons umfasst.

- Verfahren nach Anspruch 1, wobei das Gen, das BMP-3 codiert, die Aminosäuresequenz aufweist, die in Anspruch
 angegeben ist.
 - 3. Verfahren nach Anspruch 1, wobei ein Gen, das ein Protein codiert, welches mindestens die Eigenschaft von BMP-

- 3 zeigt, die Bildung von Knochen zu induzieren, eine DNA-Sequenz umfasst:
 - (a) die sich von einer DNA-Sequenz, die gemäß dem Verfahren nach Anspruch 1 erhalten wurde, in der Codonsequenz auf Grund der Degeneriertheit des genetischen Codes unterscheidet;
 - (b) die mit einer DNA-Sequenz, die gemäß dem Verlahren nach Anspruch 1 oder Absatz (a) oben erhalten wurde, unter stringenten Hybridisierungsbedingungen hybridisiert; oder
 - (c) die ein Fragment oder eine allelische Variation einer DNA-Sequenz darstellt, die gemäß dem Verfahren nach Anspruch 1 erhalten wurde.
- Verfahren nach Anspruch 3, wobei die DNA-Sequenz menschliches BMP-3 codiert.
 - 5. Verfahren nach Anspruch 3 oder 4, wobei die DNA-Sequenz eine genomische DNA-Sequenz ist.
 - 6. Verfahren nach Anspruch 3 oder 4, wobei die DNA-Sequenz eine cDNA-Sequenz ist.

15

5

- 7. Verfahren zur Herstellung eines rekombinanten Vektors, umfassend das Einfügen des Gens oder der DNA-Sequenz, die gemäß einem Verfahren nach einem der Ansprüche 1 bis 6 erhalten wurde, in funktioneller Verknüpfung mit einer Expressionskontrollsequenz in einen geeigneten Vektor.
- Zelle, transformiert mit einem Vektor, der gemäß dem Verfahren nach Anspruch 7 hergestellt wurde.
 - 9. Zelle nach Anspruch 8, die eine Säugerzelle, eine Bakterienzelle, eine Insektenzelle oder eine Hefezelle ist.
 - 10. Zelle nach Anspruch 9, die eine CHO-Zelle ist.

25

- 11. Verfahren zur Herstellung eines Proteins, das Eigenschaften von BMP-3 aufweist, umfassend die Schritte des Züchtens der Zelle nach Anspruch 9 in einem geeigneten Kulturmedium und des Isolierens des Proteins aus dem Kulturmedium.
- 30 12. Verfahren zur Herstellung eines Arzneimittels, umfassend das Kombinieren des Proteins, das gemäß dem Verfahren nach Anspruch 11 hergestellt wurde, mit einem pharmazeutisch verträglichen Vehikel.
 - 13. Verfahren nach Anspruch 12, wobei das Arzneimittel zusätzlich eine Matrix umfasst, die das Mittel an die Stelle des Knochen- oder Knorpeldefekts bringen und eine Struktur für das Induzieren von Knochen- oder Knorpelbildung zur Verfügung stellen kann.
 - Verfahren nach Anspruch 13, wobei die Matrix des Arzneimittels Hydroxyapatit, Kollagen, Polymilchsäure oder Tricalciumphosphat umfasst.
- 40 15. Verwendung eines Proteins nach Anspruch 11 für die Herstellung eines Arzneimittels zum Induzieren von Knochenoder Knorpelbildung.
 - 16. Gen, das bovines BMP-3 codiert, welches die folgende DNA-Sequenz umfasst:

45

35

50

	383	393 403		428
5	كالمتحقق والمعابل	<u> </u>		yeu gju fen y⇒ gjà yjs yel gre cil all acc acc
•	443 GA TI CIG TIC Glu Tyr Cln Tyr	142 GJU YZD GJU YYC GYC GYC 458	CER TOO CAS A	73 . 488 SG AAG CCT TAC AAG ACT TY LYS TAL
10	CIT CLE ACT CLE Leu Gla The Gla	501 CCC CCT CAT AAG Fro Paro Aago Lys	513 AGT ANG ANG ANA A Ser Lys Asn Lys L	As the ctu yil the cth we yiy cir was yir caf 233
15				553 AG ACC CTG AAG AAG GCA Un Tirr Lau Iya Iya Ala
20	ynd ynd The Cyu yry yry yyc cyy 909	TEG ATT GAA CCC	623 COS ANT TOT GCC A ANT AST CYS ALZ A	638 SA CTG TRC CTT AAA GTG TY ANY TYN LBU LYS VAL
				698 CC CCC AAS TCC TTC CAT ET FTO Lys Set Fie Asp ET FTO Lys Set Fie Asp
25				43 755 765 CA AAS GEACCOURS TEXTEROSOC- CO Lys
	776 TGTCCTTCCC ATTIC	786 파파G ; 27년		
30			_	
	CEFFCLICIC LICIC	294 304 COTTE TOFFICORO	FOR THE MAG COL	119 TCA ANT CAC COT ACC Ser Ash Kis Ale Thr
35				THE REPORT OF CLU PER CYS
40			CTO AGO ATO TER T	14 419 IC TIT CHT CHA HAC HAG He Phe Hap Clu Han Lys
45	he or or or h	54 12	469 AC ATG ACA GTA GA EN MET THE VAL GA	484 9 TCT TGT GCT TGC AGA 1 Sec Cys Alls Cys Aga
	ENCOLOGIC YYEAYC	513 523 PCAT CIRCADROTE	533 AACTOATOS.	

17. Gen, das bovines BMP-3 codiert, welches die Aminosäuresequenz aufweist, die in Anspruch 16 angegeben ist.

50

- 18. Gen, das ein Protein codiert, das mindestens die Eigenschaft von BMP-3 aufweist, die Bildung von Knochen zu induzieren, und eine DNA-Sequenz umfasst:
 - (a) die sich von einer DNA-Sequenz nach Anspruch 16 in der Codonsequenz auf Grund der Degeneriertheit des genetischen Codes unterscheidet;
 - (b) die mit einer DNA-Sequenz nach Anspruch 16 oder Absatz (a) oben unter stringenten Hybridisierungsbe-

dingungen hybridisiert; oder

- (c) die ein Fragment oder eine allelische Variation einer DNA-Sequenz nach Anspruch 16 darstellt.
- 19. DNA-Sequenz nach Anspruch 18, die menschliches BMP-3 codiert.

5

- 20. DNA-Sequenz nach Anspruch 18 oder 19, die eine genomische DNA-Sequenz ist.
- 21. DNA-Sequenz nach Anspruch 18 oder 19, die eine cDNA-Sequenz ist.
- 22. Vektor, der das Gen oder die DNA-Sequenz nach einem der Ansprüche 16 bis 21 in funktioneller Verknüpfung mit einer Expressionskontrollsequenz enthält.
 - 23. Zelle, transformiert mit einem Vektor nach Anspruch 22.
- 15 24. Zelle nach Anspruch 23, die eine Säugerzelle, eine Bakterienzelle, eine Insektenzelle oder eine Hefezelle ist.
 - 25. Zelle nach Anspruch 24, die eine CHO-Zelle ist.
- 26. Protein, das Eigenschaften von BMP-3 aufweist, das von dem Gen oder der DNA-Sequenz nach einem der Ansprüche 1 bis 21 codiert wird.
 - 27. Protein, das Eigenschaften von BMP-3 aufweist, das durch die Schritte des Züchtens in einem geeigneten Kulturmedium von einer Zelle, die mit einem Expressionsvektor transformiert ist, der ein Gen oder eine DNA-Sequenz nach einem der Ansprüche 1 bis 21 umfasst, und des Gewinnens des Proteins aus dem Kulturmedium hergestellt wird.
 - 28. Arzneimittel, das das Protein nach Anspruch 26 oder 27 und ein pharmazeutisch verträgliches Vehikel umfasst.
- 29. Arzneimittel nach Anspruch 29, das zusätzlich eine Matrix umfasst, die das Mittel an die Stelle des Knochen- oder Knorpeldefekts bringen und eine Struktur zum Induzieren von Knochen- oder Knorpelbildung zur Verfügung stellen kann.
 - Arzneimittel nach Anspruch 29, wobei die Matrix Hydroxyapatit, Kollagen, Polymilchsäure oder Tricalciumphosphat umfasst.

35

25

Revendications

- 40 Revendications pour les Etats contractants suivants : BE, CH, LI, DE, FR, GB, IT, LU, NL, SE
 - 1. Gène codant pour la BMP-3 bovine comprenant la séquence d'ADN suivante :

45

50

393 403 413 363 CARCARCANA CARROTTERS CONTROLLED STATEMENT CAR CAR CAR CAR CAR CAR CAR Ash Ash Glu Leu Ro Gly Ale 5 458 443 الله ودد محل الله ودد ودو ودو وده والله الله ودو وده وده الله وحل الله والله والله والله والله والله Giv The Gin The Life Giv hap Giv Val Tip Giv Giv Ang Lys fin The The 303 515 10 CTT COG ACT CAG CCC CCC CAG ANG ANG ANG ANA ANG ANA CAG AGG ANG CGA ier Cln Thr Gin Fro Pro Asp Lys Ser Lys Ash Lys Lys Lys Gin Ary Lys Giv त्या कर कर अर स्था कर कर कर यह का कर साम कर कर अर कर स्था कर अर कर the Gin Gin Lys Ser Gin Thr Leu Gin The Asp Giu Gin Thr Leu Lys Lys Ale 15 **£**28 623 Ary Ary Lys Gin Top Ile Giu Pro Ary Asn Cys Ale Ary Ary Cyr Isu Lys Vei 20 क्षर क्षार क्ष्म क्ष्म क्ष्म क्षर क्ष्म Asp the Ale Asp Ile Gly Trp Ser Glu Trp Tie Ile Ser Fro Lys Ser the Asp 743 GOOD THE THE THE TOT GOA GOT THE COO THE COO AND ONA ANG OTHERWATE TRATTERING Ala Tyr Tyr Cys Ser Gly Ala Cys Gln Fine Fro MRT Fro Lys 785 776 TOTOMITOM ATTICIPANA ; et 254 30 304 319 284 CENACTION PROTOCOLLY TONICORDS FOR THE AND CON FOR ANY CAC COT ACC Ser Leu Lys Pro Ser Ash His Ala Trr 249 354 Mic can then mix and her ear ear ear are one can ear are one ear are 35 Ile Gin Ser Ile Val Ary Ale Val Gly Val Val Pro Gly Ile Pro Glu Pro C/s TOT OTG CCA CAA AAG ATG TOO TOA OTG AGG ATG TTA TTG TIT GAA AAG AAG Cys Val Fro Glu Lys MIT Ser Ser Len Ser Ile Len The App Glu Asm Lys 40 455 45 भी का का दा का भूभ का छा का भर भर भर का का रहा का का सा भर han ver ver law bys var byt sto han her the ver one see one his one had 503 510 באכניניסוף אאניאניכהן כיננים מיני אאניכאבים 50

- 2. Gêne codant pour la BMP-3 bovine ayant la séquence d'acides aminés donnée à la revendication 1.
- Gène codant pour une protéine montrant au moins les propriétés de la BMP-3 pour induire la formation osseuse
 et comprenant une séquence d'ADN :
 - (a) qui diffère d'une séquence d'ADN de la revendication 1 dans la séquence de codons du fait de la dégénérescence du code génétique ;

- (b) qui s'hybride avec une séquence d'ADN de la revendication 1 ou du paragraphe (a) ci-dessus dans des conditions d'hybridation stringentes; ou
- (c) représente un fragment ou une variation allélique d'une séquence d'ADN de la revendication 1.
- 5 4. Séquence d'ADN suivant la revendication 3, qui code pour la BMP-3 humaine.
 - 5. Séquence d'ADN suivant la revendication 3 ou 4, qui est une séquence d'ADN génomique.
 - 6. Séquence d'ADN suivant la revendication 3 ou 4, qui est une séquence d'ADNc.

10

- 7. Vecteur contenant le gène ou la séquence d'ADN suivant l'une quelconque des revendications 1 à 6, en association opérationnelle avec une séquence de contrôle d'expression.
- 8. Cellule transformée avec un vecteur de la revendication 7.

15

- Cellule suivant la revendication 8, qui est une cellule mammifère, une cellule bactérienne, une cellule d'insecte ou une cellule de levure.
- 10. Cellule suivant la revendication 9, qui est une cellule CHO.

20

11. Protéine montrant des propriétés de la BMP-3, qui est codée par le gène ou la séquence d'ADN de l'une quelconque des revendications 1 à 6.

25

- 12. Protéine montrant des propriétés de la BMP-3, qui est produite par les étapes de culture dans un milieu de culture approprié d'une cellule transformée avec un vecteur d'expression comprenant un gène ou une séquence d'ADN de l'une quelconque des revendications 1 à 6, et de récupération de ladite protéine du milieu de culture précité.
- 13. Procédé de production de la protéine suivant l'une ou l'autre des revendications 11 ou 12, comprenant les étapes de culture dans un milieu de culture approprié de la cellule de la revendication 9 et d'isolement de ladite protéine du milieu de culture précité.
- 14. Composition pharmaceutique comprenant la protéine suivant l'une ou l'autre des revendications 11 ou 12 et un véhicule pharmaceutiquement acceptable.

35

30

- 15. Composition pharmaceutique suivant la revendication 14, comprenant en outre une matrice pouvant distribuer la composition au site de l'anomalie osseuse ou cartilagineuse et fournir une structure pour induire une formation osseuse ou cartilagineuse.
- 16. Composition pharmaceutique suivant la revendication 15, dans laquelle ladite matrice comprend de l'hydroxya patite, du collagène, de l'acide polylactique ou du phosphate tricalcique.
 - 17. Utilisation d'une protéine suivant l'une ou l'autre des revendications 11 ou 12 pour la préparation d'une composition pharmaceutique pour induire une formation osseuse ou cartilagineuse.

45

Revendications pour l'Etat contractant suivant : AT

1. Procédé de préparation d'un gène codant pour le BMP-3 bovin comprenant la séquence d'ADN suivante :

50

		3E3			93		40.			413					43			
	ಆರಾಜ	73C (ಯಾಗ		SG G	GGIC		r Go	CECE	SC36								
											35	וצג ה	n Gi	u Le	u ⊋-	c Gl	y Ala	
5																		
,		443					458					473					483	
	ica ca																	
	Glu Tyr	ಯಾ	ΣŽΣ.	Lys	Glu	425	Glu	V21	شتق	Glu	Glu	كتع	LVS	320	Tyt	LVS	Tre	
	-					_			_			·	_		-	•		
10				503					518					533				
	ಯಾ ಆತ	ACT	C÷T	α	∞	G.T	236	25	عدد	220	AAA	AAG	222	೧೯	163	756	<u>ಆರ್.</u>	
	ieu Gla	Ti	G <u>in</u>	377	320	وكذ	Lys	Sar	Lys	Asn	Lys	Lys	Lys	<u> </u>	3	Live	Glv	
						•	• .		•		•	•	•					
	543				•	563					578					593		
4.0	ಯಾ ಆಾ	CP.C	225	AGT	C:S	$\lambda \infty$	CIC	CE	TIT	CIT.	C2.2.	CC	ACC	CTG	220	226	GEX	
15	ನ್ನು ಆಗ																	
			-							•			٠.		• •	-		
			605					623		•			636					
	aga aga	AAG	CYY.	735	ATT	GY	α	α	330	TT	$\epsilon \infty$	ACA	ದತ	D.C	CIT	ڊي:	G:G	
	Ary Ary	Lys	<u>C] -</u>	II.	Ile	Glu	<u> </u>	وعد	ಸಿತಾ	C.3	112	وتبد	Airy	Tyr	Leu	Lys	,V <u>≥ 1</u>	
20		•						_		-		•	_			_		
	653				€5 6 .					553					693			
	ಆಲ ಗಾರ	GC.	ಆಾ	ATT.	GGC	TGG	+	جج	TGG	ATT	<u> </u>	$\tau \infty$	α	3345	TCC	TIC	ಆತ	
	Asp Pas	#la	نجز	Ξla	GĮ 'n	طحح	Ser	Clu	IIP.	Ile	Ile	Ser	520	Lys	حع	Fre	جج	
									•								-	
25		713			•		723					743		•		75£		766
			~~~	~~~				~~	J.,	~~		$\sim$						
	ಯ ಚಾ														~~~	110		
	YJS JĀ⊐ GCC JET														~~~	.16 .		16165
	Hs Iv	$\bar{x}\bar{\lambda}\bar{x}$		Ser	GŢÅ											.10		د تعیل توسط م
	yjs īvī	Ί <u>γτ</u> 77€	Cys	5e. 78	e ejà	<u>21a</u>										.10		
30	Hs Iv	Ί <u>γτ</u> 77€	Cys	5e. 78	e ejà	<u>21a</u>										116		10100"
30	yjs īvī	Ί <u>γτ</u> 77€	Cys	5e. 78	e ejà	<u>21a</u>										.10	· <b></b>	
30	HE TYP	Ty= 776 000 ;	Cys	5€∓ 78 337£	67À	<u>21a</u>	Căz	GLn				ويتق	Lys			.10		
30	terceit	Ty <del>-</del> 776 CCC :	Cys ATTT	5€∓ 78 33.7	<u>61</u> y 56 32 ;	et	Cys	Gln ,	Fine		MEE	3)	īys					
30	HE TYP	Ty <del>-</del> 776 CCC :	Cys ATTT	5€∓ 78 33.7	<u>61</u> y 56 32 ;	et	Cys	Gln G G T	Fine	ನಾ ಚಿತ್ರ	MET.	77 T.C 31 572	Lys La La		ic c	IT AC	<b>≃</b>	
	terceit	Ty <del>-</del> 776 CCC :	Cys ATTT	5€∓ 78 33.7	<u>61</u> y 56 32 ;	et	Cys	Gln G G T	Fine	ನಾ ಚಿತ್ರ	MEE	77 T.C 31 572	Lys La La		ic c	IT AC	<b>≃</b>	
30	CENCELL TOTALL	Ty <del>-</del> 776 CCC :	Cys ATTT	5€∓ 78 33.7	61y 66 85 : 64 67 TC	et	Cys	Gln G G T	Fine	er Fi	MET.	77 T.C 31 572	Lys La La		ic G	IT AC	<b>≃</b>	
	Ala Tym Tercent CTPACCT	Ty:- 776 000 ; 284 016 ;	LICE VILLE CÀS	5e- 76 32 21 22 33	61y 66 33 ; 94 97 TC	et et	304 	Gin ; ; Second	To The	7333 16 A1 164	1600 1500 1500 1500 1500 1500 1500 1500	31 31 32 TC 35 Se	IVs IS	er er	SC GC S A1	T M 2 T	≅	
	Ala Tyr TGTCCTT CTPACCT 334 ATC CAS	7y= 776 000 1 284 600 1	Cys ATTA ATTA	2: 0001	Gly 56 32 : 54 349 349 349	et et	Cys 304 CIP	Gin F To Se GGG	The Ti	RD Sin Ly 164 GTC	e con	Pino Sil To To Se GGA	Lys IS IS IS IYS	ಯ ಪ್ರಕ್ಷ ಪ್ರಧ	IC G S A 379 GAG	T ACL	ee Ee	
	Ala Tym Tercent CTPACCT	7y= 776 000 1 284 600 1	Cys ATTA ATTA	2: 0001	Gly 56 32 : 54 349 349 349	et et	Cys 304 CIP	Gin F To Se GGG	The Ti	RD Sin Ly 164 GTC	e con	Pino Sil To To Se GGA	Lys IS IS IS IYS	ಯ ಪ್ರಕ್ಷ ಪ್ರಧ	IC G S A 379 GAG	T ACL	ee Ee	
35	Ala Tyr TGTCCTT CTPACCT 334 ATC CAS	Tyr 776 CC 1 284 GIG 1 Ser	Cys ATTTO TTCT: ATTA Tle	2: 0001	Gly 56 32 : 54 349 349 349	et et	GIG Val	Gin F To Se GGG	The Ti	RD Sin Ly 164 GTC	e con	STO SE	Lys IS IS IS IYS	ಯ ಪ್ರಕ್ಷ ಪ್ರಧ	IC G S A 379 GAG	T ACL	oùe zec z	
	TERCETT  CERACIT  334  AEC CAS  ILLE GLO	776 CCC 284 CTC 287 SCT 394	Cys ATTTO TTCT: ATTA The	Ser 70 21 COLI	Gly 66 AG ; 64 ET TO 149 ACA Arg	et et GCT Ala	Cys 304 VIII GIG Val 409	GIA GGG GGG GIA	The Tier Lie GIC Val	RED RED RED RED RED Val	MET COT POST	31 24 TO 56 624 614 424	Lys E A E A E A E A I I I I I	330 600 81 Hi	SC GC S Al 375 GAG Glu	T AC A TO COT Paro	TGC Cys 439	
35	TERCETT  TERCETT  TERCETT  TRACT  TRA	77 = 77 6 CCC 284 CCC 394 CCC	Cys ATTTO TTCT: ATA TIe	Ser 70 70 70 70 70 70 70 70 70 70 70 70 70	Gly se	et et cor ala	Cys 304 CTC Val 409 TCA	GCG GCG GCG GCG GCG GCG GCG GCG GCG GCG	The Tier Idea of Control of Contr	EC No. 154 CTC Val. No.	MET CON THE	31 CA TO TO SE GLY GLY 424 TIC	TYS LYS LYS TILE	97 97 97 97 97 97	IC GG IS Al 175 GAG Glui GAA	T AC	TGC Cys 419	
35	TERCETT  CERACIT  334  AEC CAS  ILLE GLO	77 = 77 6 CCC 284 CCC 394 CCC	Cys ATTTO TTCT: ATA TIe	Ser 70 COATS 25 COCK Val	Gly se	et et cor ala	Cys 304 CTC Val 409 TCA	GCG GCG GCG GCG GCG GCG GCG GCG GCG GCG	The Tier Idea of Control of Contr	EC No. 154 CTC Val. No.	MET CON THE	31 CA TO TO SE GLY GLY 424 TIC	TYS LYS LYS TILE	97 97 97 97 97 97	IC GG IS Al 175 GAG Glui GAA	T AC	TGC Cys 419	
35	TERCETT  TERCETT  TERCETT  TRACT  TRA	77 = 77 6 CCC 284 CCC 394 CCC	Cys ATTTO TTCT: ATA TIe	Ser 70 20 COLI CIG Val AAC Lys	Gly  66  KG :  149  ACA  ATG	et et cor ala	Cys 304 CTC Val 409 TCA	GCG GCG GCG GCG GCG GCG GCG GCG GCG GCG	Fine Till Till GTC Val	EC No. 154 CTC Val. No.	MET CON THE	31 CA TO TO 56 GGA GLY 424 TIC	TYS LYS LYS TILE	er e	IC GG IS Al 175 GAG Glui GAA	T AC	TGC Cys 419	
35	TETCHIT  TET	776 284 676 284 676 284 676 867 867 867 867 867 867 867	Cys ATTTC	Ser 77 77 77 77 77 77 77 77 77 77 77 77 77	GLY  66  63  64  17  149  ALG  ALG  MET	et et corro	Cys 304 CTC Val 409 CCA Ser	Gin ; TC Giy CTC Leu	She or Ti	Room Edition (Control of the Control	MET COT STATE OF THE CO	Sin Second	Lys  19  20  ATC  Tile  TITE	484 484 484 484 484 484 484 484 484 484	SC 60	11 X X X X X X X X X X X X X X X X X X	TGC Cys 419 AAG Lys	
35	TETCHIT  CTPACTI  134  ATC CAS  ILLE GLO  TOT GISS  Cys Val.	77 = 77 6 CCC 284 CCC 284 CCC 284 CCC 284 CCC 285 CCC	Cys ATTTC	Ser 77 77 77 77 77 77 77 77 77 77 77 77 77	GLY  66  64  67  64  67  64  67  67  67  67	Ala et GCT Ala TCC Ser	Cys 304 CTC Val 409 CCA Ser CCA	Gin  , , , , , , , , , , , , , , , , , ,	She	Room Education Control of the Contro		Sin To Se GLY YIC Fine.	Lys  19  20  ATC  THE	the test of the te	SC SC SC SC NO. SC NO. SC	T ACT	E Cys 439 439 Lys	
35 40	TETCHIT  TET	77 = 77 6 CCC 284 CCC 284 CCC 284 CCC 284 CCC 285 CCC	Cys ATTTC	Ser 77 77 77 77 77 77 77 77 77 77 77 77 77	GLY  66  64  67  64  67  64  67  67  67  67	Ala et GCT Ala TCC Ser	Cys 304 CTC Val 409 CCA Ser CCA	Gin  , , , , , , , , , , , , , , , , , ,	She She was a second of the se	Room Education Control of the Contro		Sin To Se GLY YIC Fine.	Lys  19  20  ATC  THE	the test of the te	SC SC SC SC NO. SC NO. SC	T ACT	E Cys 439 439 Lys	
35 40	TOTALLET  TOTALLET  TOTALLET  TOTALLET  TOTALLET  TOTALLET  TOTALLET  TOTALLET  CVS V21  AAT GTO  Aam V21	77 = 77 6 C 284 G C C 284 C C	Cys ATTTC	Ser 77 77 77 77 77 77 77 77 77 77 77 77 77	GLY  66  64  67  64  67  67  67  67  67  67	Ala et GCT Ala TCC Ser	C/S 304 304 304 304 304 304 305 307 307 307 307 307 307 307 307 307 307	Gin GGG Gily GGC Leu AAC	She She was a second of the se	Room And		Sin To Se GLY YIC Fine.	Lys  19  20  ATC  THE	the test of the te	SC SC SC SC NO. SC NO. SC	T ACT	E Cys 439 439 Lys	
35 40	TERCETT  TER	77 = 77 6	Cys ATTITO ATTA Ile GAA Glu CTT Leu Leu	Ser 77 77 77 77 77 77 77 77 77 77 77 77 77	GLY 66 SG : 64 TO SAGA ATT ATT VEL 3	Ala et GTT Ala TCC Ser TAT	304 Val 409 Val 409 Val 523	Gin  GGG GIY  CTC Leu  AAC AET	Fine THE LI GIC Val ACC SET 469 ACC HEE	ED NO AN ACA The ACA The SSS	A COLUMN THE COLUMN TH	Sin To Se GLY YIC Fine.	Lys  19  19  10  11  TIT  TOT	the test of the te	SC SC SC SC NO. SC NO. SC	T ACT	E Cys 439 439 Lys	
35 40	TOTALLET  TOTALLET  TOTALLET  TOTALLET  TOTALLET  TOTALLET  TOTALLET  TOTALLET  CVS V21  AAT GTO  Aam V21	77 = 77 6	Cys ATTITO ATTA Ile GAA Glu CTT Leu Leu	Ser 77 77 77 77 77 77 77 77 77 77 77 77 77	GLY 66 SG : 64 TO SAGA ATT ATT VEL 3	Ala et GTT Ala TCC Ser TAT	304 Val 409 Val 409 Val 523	Gin  GGG GIY  CTC Leu  AAC AET	Fine THE LI GIC Val ACC SET 469 ACC HEE	ED NO AN ACA The ACA The SSS	A COLUMN THE COLUMN TH	Sin To Se GLY TIC Fine.	Lys  19  19  10  11  TIT  TOT	the test of the te	SC SC SC SC NO. SC NO. SC	T ACT	E Cys 439 439 Lys	
35 40	TERCETT  TER	77 = 77 6	Cys ATTITO ATTA Ile GAA Glu CTT Leu Leu	Ser 77 77 77 77 77 77 77 77 77 77 77 77 77	GLY 66 SG : 64 TO SAGA ATT ATT VEL 3	Ala et GTT Ala TCC Ser TAT	304 Val 409 Val 409 Val 523	Gin  GGG GIY  CTC Leu  AAC AET	Fine THE LI GIC Val ACC SET 469 ACC HEE	ED NO AN ACA The ACA The SSS	A COLUMN THE COLUMN TH	Sin To Se GLY TIC Fine.	Lys  19  19  10  11  TIT  TOT	the test of the te	SC SC SC SC NO. SC NO. SC	T ACT	E Cys 439 439 Lys	

ledit procédé comprenant le criblage d'une banque génomique recombinante de bovin avec des sondes comprenant des pools d'oligonucléotides conçues sur la base des séquences d'acides aminés partielles et l'isolement d'un clone positif.

- Procédé selon la revendication 1, dans lequel le gène codant pour le BMP-3 a la séquence d'acides aminés donnée dans la revendication 1.
  - 3. Procédé selon la revendicacion 1, dans lequel un gène codant pour une protéine présentant au mois la propriété

du BMP-3 d'induction de la formation de l'os comprend une séquence d'ADN :

- a) qui diffère d'une séquence d'ADN obtenue selon la procédé de la revendication 1 par la séquence de codons du fait de la dégénérescence du code génétique ;
- b) qui s'hybride avec une séquence d'ADN obtenue selon le procédé de la revendication 1 ou la section a) cidessus dans des conditions d'hybridation stringentes ; ou
- c) représente un fragment ou une variation allélique d'une séquence d'ADN obtenue selon le procédé de la revendication 1,
- 10 4. Procédé selon la revendication 3, dans lequel la séquence d'ADN code pour le BMP-3 humain.
  - 5. Procédé selon la revendication 3 ou 4, dans lequel la séquence d'ADN est une séquence d'ADN génomique.
  - 6. Procédé selon la revendication 3 ou 4, dans lequel la séquence d'ADN est une séquence d'ADNc.

15

5

- 7. Procédé de préparation d'un vecteur recombinant comprenant l'insertion du gène ou de la séquence d'ADN obtenue selon un procédé de l'une quelconque des revendications 1 à 6 en association opératoire avec une séquence de contrôle d'expression dans un vecteur adapté.
- Cellule transformés avec un vecteur préparé selon le procédé de la revendication 7.
  - Cellule selon la revendication 8, qui est une cellule mammifère, une cellule bactérienne, une cellule d'insecte ou une cellule de levure.
- 25 10. Cellule selon la revendication 9, qui est une cellule CHO.
  - 11. Procédé de production d'une protéine présentant les propriétés du BMP-3, comprenant les étapes de culture dans un milieu de culture adapté de la cellule de la revendication 9 et d'isolement de ladite protéine dudit milieu de culture.
- 30 12. Procédé de préparation d'une composition pharmaceutique comprenant la combinaison de la protéine produite selon le procédé de la revendication 11 avec un véhicule pharmaceutiquement acceptable.
  - 13. Procédé selon la revendication 12, dans lequel la composition pharmaceutique comprend en outre une matrice capable de délivrer la composition sur le site du défaut de l'os ou du cartilage et la fourniture d'une structure pour induire la formation d'os ou de cartilage.
  - 14. Procédé selon la revendication 13, dans lequel ladite matrice de ladite composition pharmaceutique comprend de l'hydroxyapatite, du collagène, de l'acide polylactique ou du phosphate tricalcique.
- 40 15. Utilisation d'une protéine selon la revendication 11 pour la préparation d'une composition pharmaceutique pour induire la formation d'os ou de cartilage.
  - 16. Gène codant pour le BMP-3 bovin comprenant la séquence d'ADN suivante :

45

35

50

5	183 193 403 413 426 CHACHANAS CASTATACAS CASTATACAS CASTA CA
10	443 458 473 466 GLA TRE CAS TRE AMS GRE GRE GAA GEA TGG GRE GAE AMS AMS CET TRE AMS ACT GLU TYE GLA TYE LYS GLU ASP GLU VAL TEP GLU GLU AMS LYS FRO TYE LYS THE
10	501 518 511 CTT CHE ACT CHE CCC CCT CAT AME MIT AME AMA AME AMA CHE MEE AME COM Leu Glin Thit Glin Pro Pro Asp ly's Set ly's Asn ly's Ly's Glin Act ly's Gly
15	543 SET GLA THE LEW GLA FACE GLA GLA THE LEW LYS LYS ALL FOR GLA GLA LYS SEE GLA THE LEW GLA FACE ASP GLA GLA THE LEW LYS LYS ALLS FOR GLA GLA LYS SEE GLA THE LEW GLA FACE ASP GLA GLA THE LEW LYS ALLS FOR GLA GLA LYS SEE GLA THE LEW GLA FACE GLA GLA THE LEW LYS ALLS
20	606 621 638 Acr, Aca, Arc Car Too Acr Car, Acr, Cor Car, Ara, Cor, Car, Ara, Cor, Arg Arg Lys Clin Tip Ile Clin Fro Arg Asn Cys Ale Arg Arg Tyr Len Lys Vel
25	653 658  GC TTC GCA GCT MT GGC TGG MAC GAA TGG MT MT TCC CCC AAG TCC TTC GCT Asp She Alla Map Ille Gly farp Ser Glu Tap Ille Ille Ser Sho Lys Ser She Asp
30	711 726 765 ect the the the character the character that the character
35	284 254 304 315 CHACTERS THE COLUMN TOWN CALL GAT ACT SET LEU LYS PRO SET AST HIS ALL THE
40	114 149 154 175 MC CHE MAT MAR GIG MAR GAT GIG GGG GTC GTC CAT GAN MAC CAT GAN CAT THAT THE GLIN SET THE VEL MAY MAR VEL GLY VEL FOR GLY THE FOR GLY FOR CYN
45	354 409 424 429 THE ONE ONLY AND AND THE THE ONLY ONLY AND
50	454  AES  AES  AES  AES  AES  AES  AES  AE

- 17. Gène codant pour le BMP-3 bovin ayant la séquence d'acides aminés donnée dans la revendication 16.
  - 18. Gène codant pour une protéine présentant au moins la propriété du BMP-3 d'induction de la formation de l'es et comprenant une séquence d'ADN :

- a) qui diffère d'une séquence d'ADN de la revendication 16 par la séquence de codons du fait de la dégénérescence du code génétique ;
- b) qui s'hybride avec une séquence d'ADN de la revendication 16 ou de la section a) ci-dessus dans des conditions d'hybridation stringentes ou
- c) représente un fragment ou une variation allélique d'une séquence d'ADN selon la revendication 16.
- 19. Séquence d'ADN selon la revendication 18, qui code pour le BMP-3 humain.
- 20. Séquence d'ADN selon la revendication 18 ou 19, qui est une séquence d'ADN génomique.
- 21. Séquence d'ADN selon la revendication 18 ou 19, qui est une séquence d'ADNc.
- 22. Vecteur contenant le gène ou la séquence d'ADN selon l'une quelconque des revendications 16 à 21 en association opératoire avec une séquence de contrôle d'expression.
- 23. Cellule transformée avec un vecteur selon la revendication 22.

5

10

15

20

25

35

40

45

50

- 24. Cellule selon la revendication 23, qui est une cellule mammifère, une cellule bactérienne, une cellule d'insecte ou une cellule de levure,
- 25. Cellule selon la revendication 24, qui est une cellule CHC.
- 26. Protéine présentant les propriétés du BMP-3 qui est encodée par le gène ou la séquence d'ADN selon l'une quelconque des revendications 1 à 21.
- 27. protéine présentant les propriétés du BMP-3 qui est produite par les étapes de culture dans un milieu de culture adapté d'une cellule transformée avec un vecteur d'expression comprenant un gêne ou la séquence d'ADN selon l'une quelconque des revendications 1 à 21, et de récupération de ladite protéine dudit milieu de culture.
- 30 28. Composition pharmaceutique comprenant la protéine selon la revendication 26 ou 27 et un véhicule pharmaceutiquement acceptable.
  - 29. Composition pharmaceutique selon la revendication 29, comprenant en outre une matrice capable de délivrer la composition sur le site du défaut de l'os ou du cartilage et la fourniture d'une structure pour induire la formation d'os ou de cartilage.
  - 30. Composition pharmaceutique selon la revendication 29, dans laquelle ladite matrice comprend de l'hydroxyapatite, du collagène, de l'acide polylactique ou du phosphate tricalcique.

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

# IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.